REx - Retrieval of Experiments
Supplementary Website for J Caldas*, N Gehlenborg*, E Kettunen, A Faisal, M Rönty, AG Nicholson, S Knuutila, A Brazma and S Kaski, "Data-Driven Information Retrieval in Heterogeneous Collections of Transcriptomics Data Links SIM2s to Malignant Pleural Mesothelioma", submitted, 2011.
For comments or questions about this website please contact Nils Gehlenborg or José Caldas.
Download Data and Source Code
- Input Files (1.4 GB)
- Gibbs Sampler (35.0 MB)
- Model Files (4.1 MB)
Please see the manuscript and the README files in the archives for further information.
View Queries from the Paper
- Case Study 1: Benign Nevi / Malignant Melanoma
- Case Study 2: Pancreatic Cancer
- Case Study 3: Glioblastoma
- Validation Study: Malignant Pleural Mesothelioma
Explore Queries
|
2 h
vs 0 in Homo sapiens
|
|
|
4 h
vs 0 in Homo sapiens
|
|
|
6 h
vs 0 in Homo sapiens
|
|
|
8 h
vs 0 in Homo sapiens
|
|
|
10 h
vs 0 in Homo sapiens
|
|
|
12 h
vs 0 in Homo sapiens
|
|
|
breast cancer
vs normal in Homo sapiens
|
|
|
breast cancer
vs normal in Homo sapiens
|
|
|
infiltrating ductal carcinoma
vs normal in Homo sapiens
|
|
|
infiltrating lobular carcinoma
vs normal in Homo sapiens
|
|
|
ataxin 1 -/-
vs wild_type in Mus musculus
|
|
|
20 umol/kg
vs 0 umol/kg in Mus musculus (cadmium & & Mtf1-loxP)
|
|
|
20 umol/kg
vs 0 umol/kg in Mus musculus (cadmium & gene_knock_out & Mtf1-Mx-cre)
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (lipopolysaccharide & 10 ng_per_mL & 4 h)
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (lipopolysaccharide & 10 ng_per_mL & 8 h)
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (none & & )
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (lipopolysaccharide & 10 ng_per_mL & 1 h)
|
|
|
ClC-6 -/- knockout
vs wild_type in Mus musculus
|
|
|
hyperglycaemic, obese and insulin resistant
vs normal in Mus musculus
|
|
|
hyperglycaemic, obese and insulin resistant
vs normal in Mus musculus
|
|
|
AIDS-KS, HIV+, nodular (late) stage
vs normal in Homo sapiens ( & skin & )
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (4 weeks)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (8 weeks)
|
|
|
2 Gy
vs 0 Gy in Homo sapiens (non responder)
|
|
|
2 Gy
vs 0 Gy in Homo sapiens (over responder)
|
|
|
astrocytic tumor
vs normal in Homo sapiens
|
|
|
glioblastoma
vs normal in Homo sapiens
|
|
|
IMP(1,3)A
vs mock in Homo sapiens
|
|
|
IMP(1,3)B
vs mock in Homo sapiens
|
|
|
Kaposi's sarcoma
vs normal in Homo sapiens ( & )
|
|
|
Kaposi's sarcoma-associated herpesvirus
vs uninfected in Homo sapiens (lymphatic endothelial cell & normal)
|
|
|
SIM2s
vs control in Homo sapiens (18 h)
|
|
|
SIM2s
vs control in Homo sapiens (24 h)
|
|
|
SIM2s
vs control in Homo sapiens (10 h)
|
|
|
SIM2s
vs control in Homo sapiens (14 h)
|
|
|
0.02 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
0.5 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
1 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
10 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
50 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
0.001 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
0.01 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
0.1 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
1 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
10 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
PGC-1 beta transgenic
vs wild_type in Mus musculus
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 2 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 1 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 8 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 24 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 48 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 72 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 96 h)
|
|
|
Akt1 -/-
vs wild_type in Mus musculus
|
|
|
ED-L2/Klf5 transgenic
vs wild_type in Mus musculus
|
|
|
Fr57E
vs mock infected in Mus musculus
|
|
|
FrCasE
vs mock infected in Mus musculus
|
|
|
50 mg/kg
vs 0 mg/kg in Mus musculus (metformin)
|
|
|
400 mg/kg
vs 0 mg/kg in Mus musculus (metformin)
|
|
|
Connexin 30-/-
vs wild_type in Mus musculus
|
|
|
Gata3 knockout
vs wild_type in Mus musculus
|
|
|
5 uM
vs 0 uM in Mus musculus (5-aza-2'-deoxycytidine)
|
|
|
pancreatic cancer
vs normal in Homo sapiens
|
|
|
experimental autoimmune encephalomyelitis (acute)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (recovery)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (relapsing)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (acute)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (recovery)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (relapsing)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (acute)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (recovery)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (relapsing)
vs normal in Rattus norvegicus
|
|
|
Foxa3 knockout
vs wild_type in Mus musculus
|
|
|
scrapie ME7
vs mock infected in Mus musculus (90 days)
|
|
|
scrapie ME7
vs mock infected in Mus musculus (120 days)
|
|
|
scrapie ME7
vs mock infected in Mus musculus (150 days)
|
|
|
bic-deficient
vs wild_type in Mus musculus (Th1)
|
|
|
bic-deficient
vs wild_type in Mus musculus (Th2)
|
|
|
non-basal-like breast cancer
vs normal in Homo sapiens
|
|
|
sporadic basal-like breast cancer
vs normal in Homo sapiens
|
|
|
bipolar disorder
vs normal in Homo sapiens
|
|
|
parp-2 deficient
vs wild_type in Mus musculus
|
|
|
essential thrombocythemia
vs normal in Homo sapiens (platelet)
|
|
|
vanadium
vs control in Homo sapiens
|
|
|
zinc
vs control in Homo sapiens
|
|
|
cirrhosis
vs normal in Rattus norvegicus
|
|
|
activated calcineurin
vs control in Rattus norvegicus
|
|
|
lacZ
vs control in Rattus norvegicus
|
|
|
miR-30a-3p siRNA duplex
vs none in Homo sapiens
|
|
|
hTERT/HPVE6/HPVE7 transfection
vs none in Homo sapiens
|
|
|
hTERT/HPVE6 transfection
vs none in Homo sapiens
|
|
|
hTERT transfection
vs none in Homo sapiens
|
|
|
hTERT/HPVE6/HPVE7/SV40t/hRas transfection
vs none in Homo sapiens
|
|
|
hTERT/HPVE6/HPVE7/SV40t transfection
vs none in Homo sapiens
|
|
|
IRS-1
vs wild_type in Mus musculus
|
|
|
IRS-4
vs wild_type in Mus musculus
|
|
|
IRS-3
vs wild_type in Mus musculus
|
|
|
IRS-2
vs wild_type in Mus musculus
|
|
|
gastrin-/gastrin-
vs wild_type in Mus musculus
|
|
|
AMPK gamma-3 R225Q mutant
vs wild_type in Mus musculus
|
|
|
bipolar disorder
vs normal in Homo sapiens (female)
|
|
|
bipolar disorder
vs normal in Homo sapiens (male)
|
|
|
arachidonic acid
vs control - albumin in Homo sapiens
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pYV) (virulent) & BALB/c)
|
|
|
interferon-gamma
vs none in Mus musculus (uninfected & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (interferon-gamma & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (interferon-gamma & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (none & C57BL/6J)
|
|
|
interferon-gamma
vs none in Mus musculus (uninfected & BALB/c)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (none & C57BL/6J)
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pTTS, pP60) (control) & C57BL/6J)
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pYV) (virulent) & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (interferon-gamma & BALB/c)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (interferon-gamma & BALB/c)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (none & BALB/c)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (none & BALB/c)
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pTTS, pP60) (control) & BALB/c)
|
|
|
SCD1 -/-
vs wild_type in Mus musculus
|
|
|
mdx
vs wild_type in Mus musculus (P14)
|
|
|
mdx
vs wild_type in Mus musculus (P28)
|
|
|
mdx
vs wild_type in Mus musculus (P112)
|
|
|
mdx
vs wild_type in Mus musculus (P28)
|
|
|
mdx
vs wild_type in Mus musculus (P56)
|
|
|
mdx
vs wild_type in Mus musculus (P112)
|
|
|
mdx
vs wild_type in Mus musculus (P14)
|
|
|
mdx
vs wild_type in Mus musculus (P23)
|
|
|
mdx
vs wild_type in Mus musculus (P28)
|
|
|
mdx
vs wild_type in Mus musculus (P56)
|
|
|
mdx
vs wild_type in Mus musculus (P112)
|
|
|
mdx
vs wild_type in Mus musculus (P14)
|
|
|
mdx
vs wild_type in Mus musculus (P23)
|
|
|
mdx
vs wild_type in Mus musculus (extraocular muscle)
|
|
|
mdx
vs wild_type in Mus musculus (gastrocnemius and soleus muscle)
|
|
|
1 d
vs 0 in Mus musculus (wild_type)
|
|
|
K14deltaNB-cateninER
vs wild_type in Mus musculus (1 d)
|
|
|
doxycycline
vs none in Homo sapiens (3 h)
|
|
|
doxycycline
vs none in Homo sapiens (6 h)
|
|
|
doxycycline
vs none in Homo sapiens (0)
|
|
|
1 h
vs 0 in Homo sapiens (doxycycline)
|
|
|
3 h
vs 0 in Homo sapiens (doxycycline)
|
|
|
6 h
vs 0 in Homo sapiens (doxycycline)
|
|
|
1 h
vs 0 in Homo sapiens (none)
|
|
|
3 h
vs 0 in Homo sapiens (none)
|
|
|
6 h
vs 0 in Homo sapiens (none)
|
|
|
doxycycline
vs none in Homo sapiens (1 h)
|
|
|
S-nitrosoglutathione plus dibutyryl cAMP
vs none in Homo sapiens (differentiated)
|
|
|
glutathione
vs none in Homo sapiens (differentiated)
|
|
|
glutathione plus dibutyryl cAMP
vs none in Homo sapiens (differentiated)
|
|
|
S-nitrosoglutathione
vs none in Homo sapiens (differentiated)
|
|
|
gastric cancer
vs normal in Homo sapiens
|
|
|
retinoic acid
vs none in Mus musculus (48 h)
|
|
|
retinoic acid
vs none in Mus musculus (6 h)
|
|
|
retinoic acid
vs none in Mus musculus (12 h)
|
|
|
clear cell sarcoma of the kidney
vs normal in Homo sapiens
|
|
|
Wilms' tumor
vs normal in Homo sapiens
|
|
|
myelodysplastic syndrome
vs normal in Homo sapiens ( & female)
|
|
|
myelodysplastic syndrome
vs normal in Homo sapiens ( & male)
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (6 h)
|
|
|
3 h
vs 0 in Homo sapiens (none)
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (18 h)
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (24 h)
|
|
|
6 h
vs 0 in Homo sapiens (none)
|
|
|
12 h
vs 0 in Homo sapiens (none)
|
|
|
18 h
vs 0 in Homo sapiens (none)
|
|
|
24 h
vs 0 in Homo sapiens (none)
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (3 h)
|
|
|
dexamethasone
vs none in Homo sapiens (4 h)
|
|
|
dexamethasone
vs none in Homo sapiens (16 h)
|
|
|
lipopolysaccharide
vs none in Homo sapiens (adult)
|
|
|
benign nevi
vs normal in Homo sapiens
|
|
|
malignant melanoma
vs normal in Homo sapiens
|
|
|
olfactory bulbectomy
vs sham surgery in Mus musculus (5 d)
|
|
|
Dysf-/-
vs wild_type in Mus musculus (left ventricular myocardium)
|
|
|
Dysf-/-
vs wild_type in Mus musculus (skeletal muscle)
|
|
|
ovalbumin
vs control in Mus musculus (wild_type & BALB/c)
|
|
|
ovalbumin
vs control in Mus musculus (RAG null mutant & BALB-RAG)
|
|
|
Nix null mutant
vs wild_type in Mus musculus
|
|
|
KLF15 null
vs wild_type in Mus musculus (liver)
|
|
|
KLF15 null
vs wild_type in Mus musculus (quadriceps skeletal muscle)
|
|
|
vitamin A deficient diet
vs control diet in Rattus norvegicus
|
|
|
Lim1 mutant
vs wild_type in Mus musculus
|
|
|
ketogenic diet
vs control diet in Mus musculus
|
|
|
LEDGF knockdown
vs control in Homo sapiens
|
|
|
aire -/-
vs wild_type in Mus musculus
|
|
|
Kin-
vs wild_type in Mus musculus (cAMP & 24 h)
|
|
|
Kin-
vs wild_type in Mus musculus (control & 0)
|
|
|
Kin-
vs wild_type in Mus musculus (cAMP & 2 h)
|
|
|
Kin-
vs wild_type in Mus musculus (cAMP & 6 h)
|
|
|
12 h
vs 0 in Homo sapiens
|
|
|
24 h
vs 0 in Homo sapiens
|
|
|
12 h
vs 0 in Homo sapiens
|
|
|
24 h
vs 0 in Homo sapiens
|
|
|
empty pBabe transduced
vs none in Homo sapiens
|
|
|
hTERT transduced
vs none in Homo sapiens
|
|
|
RP1 knockout
vs wild_type in Mus musculus (10 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (14 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (7 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (18 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (21 d)
|
|
|
LDLR-/-
vs wild_type in Mus musculus (high fat diet)
|
|
|
LDLR-/-
vs wild_type in Mus musculus (low fat diet)
|
|
|
carcinoma in situ lesion
vs normal in Homo sapiens (bladder)
|
|
|
muscle invasive carcinoma
vs normal in Homo sapiens (bladder)
|
|
|
superficial transitional cell carcinoma without surrounding carcinoma in situ lesion
vs normal in Homo sapiens (bladder)
|
|
|
superficial transitional cell carcinoma with surrounding carcinoma in situ lesion
vs normal in Homo sapiens (bladder)
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart intra-ventricular septum)
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart left ventricle free wall)
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart intra-ventricular septum)
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart left ventricle free wall)
|
|
|
1,25-dihydroxyvitamin D3
vs control in Homo sapiens
|
|
|
mdx
vs wild_type in Mus musculus
|
|
|
mild spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 21 d)
|
|
|
moderate spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 21 d)
|
|
|
severe spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 21 d)
|
|
|
mild spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 2 d)
|
|
|
moderate spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 2 d)
|
|
|
severe spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 2 d)
|
|
|
IL-26
vs control - untreated in Homo sapiens
|
|
|
IL-24
vs control - untreated in Homo sapiens
|
|
|
IL-22
vs control - untreated in Homo sapiens
|
|
|
IL-20
vs control - untreated in Homo sapiens
|
|
|
IL-19
vs control - untreated in Homo sapiens
|
|
|
early HIV infection
vs uninfected in Homo sapiens (CD4+ T cell)
|
|
|
early HIV infection
vs uninfected in Homo sapiens (CD8+ T cell)
|
|
|
non-progressive HIV infection
vs uninfected in Homo sapiens (CD4+ T cell)
|
|
|
non-progressive HIV infection
vs uninfected in Homo sapiens (CD8+ T cell)
|
|
|
chronic HIV infection
vs uninfected in Homo sapiens (CD4+ T cell)
|
|
|
chronic HIV infection
vs uninfected in Homo sapiens (CD8+ T cell)
|
|
|
Pseudomonas aeruginosa
vs uninfected in Homo sapiens
|
|
|
respiratory syncytial virus
vs uninfected in Homo sapiens
|
|
|
Rett syndrome
vs normal in Homo sapiens
|
|
|
HDAC1-/-
vs wild_type in Mus musculus
|
|
|
PU.1 deficient
vs wild_type in Mus musculus
|
|
|
PGC-1alpha null
vs wild_type in Mus musculus
|
|
|
Irf6 null
vs wild_type in Mus musculus
|
|
|
chronic myelogenous leukemia
vs normal in Homo sapiens
|
|
|
vulvar intraepithelial neoplasia
vs normal in Homo sapiens
|
|
|
endometriosis
vs normal in Homo sapiens (early secretory phase)
|
|
|
endometriosis
vs normal in Homo sapiens (mid secretory phase)
|
|
|
endometriosis
vs normal in Homo sapiens (proliferative phase)
|
|
|
non-tumorigenic cancer cell
vs normal in Homo sapiens
|
|
|
non-tumorigenic cancer cell
vs normal in Homo sapiens
|
|
|
Rs1h null
vs wild_type in Mus musculus
|
|
|
LmnaH222P/H222P
vs wild_type in Mus musculus
|
|
|
LmnaH222P/+
vs wild_type in Mus musculus
|
|
|
smoker
vs non-smoker in Homo sapiens (alveolar macrophage & male)
|
|
|
Klf9 null
vs wild_type in Mus musculus
|
|
|
calorie-restricted diet
vs normal diet in Mus musculus (5 months)
|
|
|
FoxO deficient
vs wild_type in Mus musculus (hematopoietic stem cell)
|
|
|
FoxO deficient
vs wild_type in Mus musculus (myeloid progenitor cell)
|
|
|
MyD88 null
vs wild_type in Mus musculus (Chlamydia pneumoniae)
|
|
|
Chlamydia pneumoniae
vs mock infected in Mus musculus (MyD88 null)
|
|
|
Chlamydia pneumoniae
vs mock infected in Mus musculus (wild_type)
|
|
|
MyD88 null
vs wild_type in Mus musculus (mock infected)
|
|
|
palmitate
vs control - BSA in Mus musculus
|
|
|
smoker
vs non-smoker in Homo sapiens (male)
|
|
|
sodium pyruvate
vs none in Mus musculus
|
|
|
creatine
vs control in Mus musculus
|
|
|
168 h
vs 0 in Rattus norvegicus
|
|
|
6 h
vs 0 in Rattus norvegicus
|
|
|
10 h
vs 0 in Rattus norvegicus
|
|
|
13 h
vs 0 in Rattus norvegicus
|
|
|
18 h
vs 0 in Rattus norvegicus
|
|
|
24 h
vs 0 in Rattus norvegicus
|
|
|
36 h
vs 0 in Rattus norvegicus
|
|
|
48 h
vs 0 in Rattus norvegicus
|
|
|
72 h
vs 0 in Rattus norvegicus
|
|
|
96 h
vs 0 in Rattus norvegicus
|
|
|
chronic lymphocytic leukemia
vs normal in Homo sapiens (B lymphocyte)
|
|
|
multiple myeloma
vs normal in Homo sapiens (plasma cell)
|
|
|
Waldenstrom's macroglobulinemia
vs normal in Homo sapiens (B lymphocyte)
|
|
|
Waldenstrom's macroglobulinemia
vs normal in Homo sapiens (plasma cell)
|
|
|
epidermal growth factor
vs none in Rattus norvegicus (4 h)
|
|
|
epidermal growth factor
vs none in Rattus norvegicus (12 h)
|
|
|
polycystic ovary syndrome
vs normal in Homo sapiens
|
|
|
calorie-restricted diet
vs normal diet in Mus musculus (4 months)
|
|
|
sulfur dioxide
vs none in Rattus norvegicus (spontaneously hypertensive)
|
|
|
sulfur dioxide
vs none in Rattus norvegicus (Sprague Dawley)
|
|
|
dark reared
vs control in Mus musculus
|
|
|
monocular deprivation left eyelid sutured
vs control in Mus musculus
|
|
|
monocular deprivation right eyelid sutured
vs control in Mus musculus
|
|
|
dark reared
vs control in Mus musculus
|
|
|
monocular deprivation left eyelid sutured
vs control in Mus musculus
|
|
|
monocular deprivation right eyelid sutured
vs control in Mus musculus
|
|
|
dark reared
vs control in Mus musculus
|
|
|
monocular deprivation left eyelid sutured
vs control in Mus musculus
|
|
|
monocular deprivation right eyelid sutured
vs control in Mus musculus
|
|
|
pituitary adenoma predisposition
vs normal in Homo sapiens
|
|
|
septic peritonitis
vs reference in Mus musculus
|
|
|
hypothermic - 32 degree_C
vs control - 37 degree_C in Homo sapiens
|
|
|
4 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
12 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
24 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
48 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
4 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
12 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
24 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
48 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
4 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
12 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
24 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
48 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
4 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
12 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
24 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
48 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
quercetin
vs none in Mus musculus (wild_type & colon)
|
|
|
quercetin
vs none in Mus musculus (POR null & ileum)
|
|
|
POR null
vs wild_type in Mus musculus (none & ileum)
|
|
|
quercetin
vs none in Mus musculus (POR null & colon)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & ileum)
|
|
|
quercetin
vs none in Mus musculus (wild_type & ileum)
|
|
|
quercetin
vs none in Mus musculus (POR null & jejunum)
|
|
|
POR null
vs wild_type in Mus musculus (none & colon)
|
|
|
POR null
vs wild_type in Mus musculus (none & jejunum)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & jejunum)
|
|
|
quercetin
vs none in Mus musculus (wild_type & jejunum)
|
|
|
quercetin
vs none in Mus musculus (POR null & liver)
|
|
|
POR null
vs wild_type in Mus musculus (none & liver)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & liver)
|
|
|
quercetin
vs none in Mus musculus (wild_type & liver)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & colon)
|
|
|
Brg1 null
vs wild_type in Mus musculus
|
|
|
beta4-/-
vs wild_type in Mus musculus
|
|
|
bipolar disorder
vs normal in Homo sapiens
|
|
|
Gyk knockout
vs wild_type in Mus musculus
|
|
|
SCD1-/-
vs wild_type in Mus musculus (control diet)
|
|
|
very low fat, high carbohydrate diet
vs control diet in Mus musculus (SCD1-/-)
|
|
|
very low fat, high carbohydrate diet
vs control diet in Mus musculus (wild_type)
|
|
|
SCD1-/-
vs wild_type in Mus musculus (very low fat, high carbohydrate diet)
|
|
|
lymph node metastasis
vs normal in Homo sapiens
|
|
|
metastatic growth phase melanoma
vs normal in Homo sapiens
|
|
|
lipopolysaccharide
vs control in Mus musculus (DUSP1-/-)
|
|
|
lipopolysaccharide
vs control in Mus musculus (DUSP1+/+)
|
|
|
KLF7-/-
vs wild_type in Mus musculus
|
|
|
lipopolysaccharide
vs none in Homo sapiens (low response)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 16 h)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 48 h)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (sham surgery & 0)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 2 h)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 8 h)
|
|
|
Lieber-DeCarli diet (36% calories from ethanol)
vs control diet in Rattus norvegicus
|
|
|
Crohn's disease
vs normal in Homo sapiens (female)
|
|
|
ulcerative colitis
vs normal in Homo sapiens (female)
|
|
|
Crohn's disease
vs normal in Homo sapiens (male)
|
|
|
ulcerative colitis
vs normal in Homo sapiens (male)
|
|
|
3H-1,2-dithiole-3-thione
vs none in Rattus norvegicus
|
|
|
vanadyl sulfate
vs none in Rattus norvegicus (diabetes mellitus)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (none)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (vanadyl sulfate)
|
|
|
vanadyl sulfate
vs none in Rattus norvegicus (normal)
|
|
|
chronic constriction
vs sham surgery in Rattus norvegicus (21 d)
|
|
|
partial sciatic nerve ligation
vs sham surgery in Rattus norvegicus (21 d)
|
|
|
FGFR3-K650E
vs wild_type in Rattus norvegicus
|
|
|
spinal cord contusion
vs none in Rattus norvegicus
|
|
|
reinnervation of rat muscle
vs none in Rattus norvegicus
|
|
|
Gata-1(-/-)
vs wild_type in Mus musculus
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
diabetes-induced erectile dysfunction
vs normal in Rattus norvegicus
|
|
|
glipizide + metformin
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
metformin
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
rosiglitazone
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
soy isoflavone extract
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
glipizide
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (female)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (male)
|
|
|
breast cancer
vs normal in Homo sapiens
|
|
|
acute hypotension
vs normal in Rattus norvegicus
|
|
|
amoxicillin
vs none in Rattus norvegicus (colon & 21 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (distal small intestine & 21 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (proximal small intestine & 21 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (distal small intestine & 17 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (proximal small intestine & 17 d)
|
|
|
4OH-tamoxifen
vs none in Homo sapiens (ERalpha transfected)
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERalpha transfected)
|
|
|
4OH-tamoxifen
vs none in Homo sapiens (ERbeta transfected)
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERbeta transfected)
|
|
|
4OH-tamoxifen
vs none in Homo sapiens (ERalpha/beta transfected)
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERalpha/beta transfected)
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERalpha expression)
|
|
|
17beta-estradiol
vs none in Homo sapiens (lacZ expression)
|
|
|
mutant fumarate hydratase
vs wild_type in Homo sapiens
|
|
|
eNOS knockout
vs wild_type in Mus musculus
|
|
|
Pmp22-/-
vs wild_type in Mus musculus (B cell & P4)
|
|
|
Trembler
vs wild_type in Mus musculus (B cell & P4)
|
|
|
neo-resistant
vs wild_type in Homo sapiens (none)
|
|
|
platelet-derived growth factor
vs none in Homo sapiens (PDGF-A dominant-negative)
|
|
|
PDGF-A dominant-negative
vs wild_type in Homo sapiens (none)
|
|
|
ischemic cardiomyopathy
vs normal in Homo sapiens
|
|
|
non-ischemic cardiomyopathy
vs normal in Homo sapiens
|
|
|
dexamethasone
vs none in Homo sapiens (8 h)
|
|
|
interferon gamma
vs none in Homo sapiens (8 h)
|
|
|
dexamethasone
vs none in Homo sapiens (24 h)
|
|
|
interferon gamma
vs none in Homo sapiens (24 h)
|
|
|
human stem cell engraftment
vs none in Homo sapiens (Capra hircus & liver)
|
|
|
arteriotomy
vs control in Rattus norvegicus (4 h)
|
|
|
arteriotomy
vs control in Rattus norvegicus (7 d)
|
|
|
arteriotomy
vs control in Rattus norvegicus (48 h)
|
|
|
Cited2 -/-
vs wild_type in Mus musculus
|
|
|
PSD95/dlgh4 -/-
vs wild_type in Mus musculus
|
|
|
SAP102/dlgh3 -/Y
vs wild_type in Mus musculus
|
|
|
neuromedin U
vs none in Mus musculus (6 h)
|
|
|
neuromedin U
vs none in Mus musculus (12 h)
|
|
|
neuromedin U
vs none in Mus musculus (0.75 h)
|
|
|
neuromedin U
vs none in Mus musculus (3 h)
|
|
|
severe acute respiratory syndrome
vs normal in Homo sapiens
|
|
|
interferon alpha
vs none in Homo sapiens (none)
|
|
|
primed with interferon gamma
vs none in Homo sapiens (interferon alpha)
|
|
|
primed with interferon gamma
vs none in Homo sapiens (none)
|
|
|
interferon alpha
vs none in Homo sapiens (primed with interferon gamma)
|
|
|
burn sepsis
vs normal in Rattus norvegicus
|
|
|
sepsis
vs normal in Rattus norvegicus
|
|
|
dermatomyositis
vs normal in Homo sapiens
|
|
|
valproic acid
vs none in Homo sapiens (normal)
|
|
|
polycystic ovary syndrome
vs normal in Homo sapiens (none)
|
|
|
valproic acid
vs none in Homo sapiens (normal)
|
|
|
polycystic ovary syndrome
vs normal in Homo sapiens (none)
|
|
|
imatinib
vs none in Homo sapiens
|
|
|
camptothecin
vs none in Homo sapiens
|
|
|
aortic stenosis
vs normal in Homo sapiens
|
|
|
congestive cardiomyopathy
vs normal in Homo sapiens
|
|
|
hypertrophic cardiomyopathy
vs normal in Homo sapiens
|
|
|
idiopathic cardiomyopathy
vs normal in Homo sapiens
|
|
|
idiopathic dilated cardiomyopathy
vs normal in Homo sapiens
|
|
|
ischemic cardiomyopathy
vs normal in Homo sapiens
|
|
|
post-partum cardiomyopathy
vs normal in Homo sapiens
|
|
|
viral cardiomyopathy
vs normal in Homo sapiens
|
|
|
familial cardiomyopathy
vs normal in Homo sapiens
|
|
|
alpha-1 antitrypsin deficiency-related emphysema
vs normal in Homo sapiens
|
|
|
emphysema
vs normal in Homo sapiens
|
|
|
caloric restriction
vs control diet in Mus musculus (DF)
|
|
|
caloric restriction
vs control diet in Mus musculus (NL)
|
|
|
diabetic nephropathy
vs normal in Homo sapiens
|
|
|
GFAP+/+
vs wild_type in Mus musculus (23 d)
|
|
|
GFAP+/+
vs wild_type in Mus musculus (120 d)
|
|
|
sporadic amyotrophic lateral sclerosis
vs reference in Homo sapiens
|
|
|
6 h
vs 0 in Homo sapiens (ambient pressure)
|
|
|
24 h
vs 0 in Homo sapiens (ambient pressure)
|
|
|
48 h
vs 0 in Homo sapiens (ambient pressure)
|
|
|
pulmonary arterial hypertension
vs normal in Homo sapiens
|
|
|
stained
vs untreated in Rattus norvegicus (none & )
|
|
|
stained
vs untreated in Rattus norvegicus (clofibric acid & 0.29 %)
|
|
|
stained
vs untreated in Rattus norvegicus (clofibric acid & 0.54 %)
|
|
|
18 h
vs 0 in Homo sapiens
|
|
|
36 h
vs 0 in Homo sapiens
|
|
|
Abca1 +/-
vs wild_type in Mus musculus
|
|
|
Cdk4 +/-
vs wild_type in Mus musculus
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (Gata4+/-)
|
|
|
Gata4+/-
vs wild_type in Mus musculus (sham surgery)
|
|
|
Gata4+/-
vs wild_type in Mus musculus (transverse aortic constriction)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (wild_type)
|
|
|
aldosterone
vs control in Mus musculus
|
|
|
100 m
vs 0 in Mus musculus (SOCS3-/-)
|
|
|
400 m
vs 0 in Mus musculus (SOCS3-/-)
|
|
|
high tidal volume ventilation
vs control in Rattus norvegicus (ventilation-associated lung injury (VALI) sensitive & Brown Norway)
|
|
|
high tidal volume ventilation
vs control in Rattus norvegicus (ventilation-associated lung injury (VALI) resistant & Dahl salt-sensitive)
|
|
|
genistein diet
vs control diet in Rattus norvegicus
|
|
|
soy protein isolate diet
vs control diet in Rattus norvegicus
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 5 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 6 h)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 6 h)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 5 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 8 d)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 8 d)
|
|
|
2 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 19 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 19 d)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 19 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 24 h)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 24 h)
|
|
|
synovial sarcoma
vs normal in Mus musculus
|
|
|
21 d
vs 0 in Rattus norvegicus (4-6 months & trained & cognitively impaired)
|
|
|
21 d
vs 0 in Rattus norvegicus (4-6 months & trained & cognitively unimpaired)
|
|
|
21 d
vs 0 in Rattus norvegicus (24-26 months & trained & cognitively unimpaired)
|
|
|
dermatomyositis
vs normal in Homo sapiens
|
|
|
EGFP transgenic
vs wild_type in Mus musculus
|
|
|
EYFP transgenic
vs wild_type in Mus musculus
|
|
|
familial combined hyperlipidemia
vs normal in Homo sapiens
|
|
|
severe malarial anaemia
vs normal in Homo sapiens
|
|
|
uncomplicated malaria
vs normal in Homo sapiens
|
|
|
ketogenic diet
vs control diet in Rattus norvegicus
|
|
|
kainate
vs control in Rattus norvegicus (6 h)
|
|
|
kainate
vs control in Rattus norvegicus (24 h)
|
|
|
kainate
vs control in Rattus norvegicus (1 h)
|
|
|
kainate
vs control in Rattus norvegicus (72 h)
|
|
|
kainate
vs control in Rattus norvegicus (240 h)
|
|
|
1 d
vs 0 in Homo sapiens (female)
|
|
|
3 d
vs 0 in Homo sapiens (female)
|
|
|
14 d
vs 0 in Homo sapiens (female)
|
|
|
1 d
vs 0 in Homo sapiens (male)
|
|
|
3 d
vs 0 in Homo sapiens (male)
|
|
|
14 d
vs 0 in Homo sapiens (male)
|
|
|
1 d
vs 0 in Homo sapiens (male)
|
|
|
acute rejection
vs normal donor in Homo sapiens (peripheral blood)
|
|
|
renal dysfunction without rejection
vs normal donor in Homo sapiens (peripheral blood)
|
|
|
well-functioning transplant
vs normal donor in Homo sapiens (peripheral blood)
|
|
|
acute rejection
vs normal donor in Homo sapiens (kidney)
|
|
|
renal dysfunction without rejection
vs normal donor in Homo sapiens (kidney)
|
|
|
well-functioning transplant
vs normal donor in Homo sapiens (kidney)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (2 d)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (10 d)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (21 d)
|
|
|
age-related macular degeneration
vs normal in Homo sapiens
|
|
|
transforming growth factor beta
vs none in Homo sapiens (idiopathic pulmonary fibrosis)
|
|
|
idiopathic pulmonary fibrosis
vs normal in Homo sapiens (none)
|
|
|
idiopathic pulmonary fibrosis
vs normal in Homo sapiens (transforming growth factor beta)
|
|
|
transforming growth factor beta
vs none in Homo sapiens (normal)
|
|
|
scleroderma-associated pulmonary fibrosis
vs normal in Homo sapiens (none)
|
|
|
scleroderma-associated pulmonary fibrosis
vs normal in Homo sapiens (transforming growth factor beta)
|
|
|
transforming growth factor beta
vs none in Homo sapiens (scleroderma-associated pulmonary fibrosis)
|
|
|
EWS-FL1 transfected
vs mock transfected in Homo sapiens
|
|
|
glaucoma
vs normal in Homo sapiens
|
|
|
3 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
6 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
Anaplasma phagocytophilum
vs uninfected in Homo sapiens (24 h)
|
|
|
heat-killed Anaplasma phagocytophilum
vs uninfected in Homo sapiens (24 h)
|
|
|
heat-killed HL60 cell lysate
vs uninfected in Homo sapiens (24 h)
|
|
|
9 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
HL60 cell lysate
vs uninfected in Homo sapiens (24 h)
|
|
|
Staphylococcus aureus
vs uninfected in Homo sapiens (24 h)
|
|
|
24 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
HIV-1 infected
vs normal in Homo sapiens (none)
|
|
|
tumor necrosis factor alpha
vs none in Homo sapiens (normal)
|
|
|
environmental enrichment
vs control in Rattus norvegicus (kainic acid & early-life seizures)
|
|
|
environmental enrichment
vs control in Rattus norvegicus (control & reference)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
erythropoietin
vs none in Mus musculus (hypoxic-ischemic injury)
|
|
|
hypoxic-ischemic injury
vs none in Mus musculus (none)
|
|
|
growth hormone
vs control in Mus musculus (0.5 h)
|
|
|
growth hormone
vs control in Mus musculus (4 h)
|
|
|
growth hormone
vs control in Mus musculus (48 h)
|
|
|
4 d
vs 0 in Mus musculus (PPARgamma2 transfection)
|
|
|
10 d
vs 0 in Mus musculus (PPARgamma2 transfection)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (2 d)
|
|
|
early B-cell factor 1 transfection
vs empty vector in Mus musculus (4 d)
|
|
|
early B-cell factor 1 transfection
vs empty vector in Mus musculus (0)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (4 d)
|
|
|
early B-cell factor 1 transfection
vs empty vector in Mus musculus (10 d)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (10 d)
|
|
|
4 d
vs 0 in Mus musculus (early B-cell factor 1 transfection)
|
|
|
10 d
vs 0 in Mus musculus (early B-cell factor 1 transfection)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (0)
|
|
|
2 d
vs 0 in Mus musculus (empty vector)
|
|
|
4 d
vs 0 in Mus musculus (empty vector)
|
|
|
10 d
vs 0 in Mus musculus (empty vector)
|
|
|
2 d
vs 0 in Mus musculus (PPARgamma2 transfection)
|
|
|
malignant pleural mesothelioma
vs normal in Homo sapiens ( & pleura)
|
|
|
glycogen synthase -/-
vs wild_type in Mus musculus (medial gastrocnemius)
|
|
|
GSL30
vs wild_type in Mus musculus (medial gastrocnemius)
|
|
|
glycogen synthase -/-
vs wild_type in Mus musculus (anterior tibialis)
|
|
|
glycogen synthase -/-
vs wild_type in Mus musculus (liver)
|
|
|
arginine deprivation
vs normal in Rattus norvegicus (normal)
|
|
|
tumorigenic
vs normal in Rattus norvegicus (arginine deprivation)
|
|
|
tumorigenic
vs normal in Rattus norvegicus (normal)
|
|
|
arginine deprivation
vs normal in Rattus norvegicus (tumorigenic)
|
|
|
LG100268
vs none in Rattus norvegicus (individual sample)
|
|
|
LG100268
vs none in Rattus norvegicus (three pooled samples)
|
|
|
LG100268
vs none in Rattus norvegicus (two pooled samples)
|
|
|
lateral fluid percussion-induced injury
vs sham in Rattus norvegicus (Rattus norvegicus & 8 h)
|
|
|
0.5 h
vs 0 in Rattus norvegicus (sham & Rattus norvegicus)
|
|
|
8 h
vs 0 in Rattus norvegicus (sham & Rattus norvegicus)
|
|
|
lateral fluid percussion-induced injury
vs sham in Rattus norvegicus (Rattus norvegicus & 0.5 h)
|
|
|
Alzheimer's disease
vs normal in Homo sapiens
|
|
|
Parkinson's disease
vs normal in Homo sapiens
|
|
|
progressive supranuclear palsy
vs normal in Homo sapiens
|
|
|
lung adenocarcinoma
vs normal in Homo sapiens (Homo sapiens)
|
|
|
PKB alpha null
vs wild_type in Mus musculus (24 h)
|
|
|
PKB alpha null
vs wild_type in Mus musculus (48 h)
|
|
|
PKB alpha null
vs wild_type in Mus musculus (0)
|
|
|
2 h
vs 0 in Mus musculus (PKB alpha null)
|
|
|
24 h
vs 0 in Mus musculus (PKB alpha null)
|
|
|
48 h
vs 0 in Mus musculus (PKB alpha null)
|
|
|
2 h
vs 0 in Mus musculus (wild_type)
|
|
|
24 h
vs 0 in Mus musculus (wild_type)
|
|
|
48 h
vs 0 in Mus musculus (wild_type)
|
|
|
PKB alpha null
vs wild_type in Mus musculus (2 h)
|
|
|
sodium tungstate
vs none in Rattus norvegicus (diabetes mellitus)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (none)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (sodium tungstate)
|
|
|
sodium tungstate
vs none in Rattus norvegicus (normal)
|
|
|
Aldh5a1-/-
vs wild_type in Mus musculus (cerebellum)
|
|
|
Aldh5a1-/-
vs wild_type in Mus musculus (cortex)
|
|
|
Aldh5a1-/-
vs wild_type in Mus musculus (hippocampus)
|
|
|
SCA1 model
vs wild_type in Mus musculus (cerebellum & 11 weeks)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 4 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 4 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 7 d)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 7 d)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 7 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 7 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 12 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 12 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 21 d)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 21 d)
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (14 d)
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (28 d)
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (3)
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (7 d)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 90 m)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 120 m)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (control & 0)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 30 m)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 60 m)
|
|
|
12 h
vs 0 in Mus musculus (control)
|
|
|
24 h
vs 0 in Mus musculus (control)
|
|
|
interleukin-2
vs control in Mus musculus (12 h)
|
|
|
interleukin-2
vs control in Mus musculus (24 h)
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & cerebral cortex)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & cerebral cortex)
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & hippocampus)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & hippocampus)
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & cerebral cortex)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & cerebral cortex)
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & hippocampus)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & hippocampus)
|
|
|
HIPK2 dominant-negative
vs wild_type in Mus musculus
|
|
|
fetal growth restriction
vs normal in Homo sapiens
|
|
|
preeclampsia
vs normal in Homo sapiens
|
|
|
6 h
vs 0 h in Homo sapiens (SN38 sensitive)
|
|
|
12 h
vs 0 h in Homo sapiens (SN38 sensitive)
|
|
|
24 h
vs 0 h in Homo sapiens (SN38 sensitive)
|
|
|
6 h
vs 0 h in Homo sapiens
|
|
|
12 h
vs 0 h in Homo sapiens
|
|
|
24 h
vs 0 h in Homo sapiens
|
|
|
D374Y-PCSK9
vs wild_type in Homo sapiens
|
|
|
Lactobacillus plantarum WCFS1
vs mock infected in Homo sapiens
|
|
|
adenocarcinoma
vs normal in Homo sapiens ( & & prostate)
|
|
|
1 m
vs 0 m in Homo sapiens (cooked broccoli)
|
|
|
ALDHhiSSClo neural stem cells transplantation
vs untreated in Mus musculus (nmd)
|
|
|
nmd
vs wild_type in Mus musculus (untreated)
|
|
|
bicuculline
vs none in Mus musculus
|
|
|
forskolin + rolipram in Mg2+-free ACSF
vs none in Mus musculus
|
|
|
N-methyl-D-aspartic acid
vs none in Mus musculus
|
|
|
Upf2fl/fl;LckCre
vs wild_type in Mus musculus (thymocyte)
|
|
|
Upf2fl/fl;LysMCre
vs wild_type in Mus musculus (macrophage)
|
|
|
E2F2-/-
vs wild_type in Mus musculus (0 h)
|
|
|
48 h
vs 0 h in Mus musculus (E2F2-/-)
|
|
|
48 h
vs 0 h in Mus musculus (wild_type)
|
|
|
E2F2-/-
vs wild_type in Mus musculus (48 h)
|
|
|
mdm2 knock-out
vs wild_type in Mus musculus
|
|
|
acute myeloid leukemia
vs normal in Mus musculus
|
|
|
Ercc1
vs wild_type in Mus musculus
|
|
|
Ela-Tgfa
vs wild_type in Mus musculus
|
|
|
p48-Cre;KrasG12D
vs wild_type in Mus musculus
|
|
|
p48-Cre;KrasG12D;Ela-Tgfa
vs wild_type in Mus musculus
|
|
|
CREM(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 1080 m)
|
|
|
CREM(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 40 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (none & 0 m)
|
|
|
CREM(-/-)
vs wild_type in Mus musculus (none & 0 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 40 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 120 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 720 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 1080 m)
|
|
|
5 ug
vs 0 ug in Rattus norvegicus (triiodothyronine & 1 h)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (Wistar Kyoto)
|
|
|
pkd1 -/-
vs wild_type in Mus musculus (flow)
|
|
|
pkd1 -/-
vs wild_type in Mus musculus (no flow)
|
|
|
diethylstilbestrol
vs control in Rattus norvegicus (ACI)
|
|
|
diethylstilbestrol
vs control in Rattus norvegicus (Brown Norway)
|
|
|
diethylstilbestrol
vs control in Rattus norvegicus (Copenhagen)
|
|
|
Parkinson's disease
vs normal in Homo sapiens (female)
|
|
|
Parkinson's disease
vs normal in Homo sapiens (male)
|
|
|
clozapine
vs none in Mus musculus
|
|
|
haloperidol
vs none in Mus musculus
|
|
|
SCA1 knock-in
vs SCA1 wild_type in Mus musculus (5 weeks)
|
|
|
SCA7 knock-in
vs SCA7 wild_type in Mus musculus (9 weeks)
|
|
|
1 h
vs 0 h in Rattus norvegicus (no exercise & polysomal_RNA)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 3 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 4 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (uninfected & 0 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 8 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 12 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 2 d)
|
|
|
Leishmania donovani
vs uninfected in Mus musculus (Mus musculus)
|
|
|
Leishmania major
vs uninfected in Mus musculus (Mus musculus)
|
|
|
phagocytosis of latex beads
vs uninfected in Mus musculus (Mus musculus)
|
|
|
C85 tumor cell conditioned media
vs normal growth media (C85) in Rattus norvegicus (single exposure)
|
|
|
Nrl null
vs wild_type in Mus musculus (2 days)
|
|
|
Nrl null
vs wild_type in Mus musculus (10 days)
|
|
|
Nrl null
vs wild_type in Mus musculus (60 days)
|
|
|
interferon alpha
vs control in Homo sapiens (endothelial cell)
|
|
|
interferon gamma
vs control in Homo sapiens (endothelial cell)
|
|
|
interferon alpha
vs control in Homo sapiens (fibroblast)
|
|
|
insulin
vs none in Homo sapiens
|
|
|
insulin
vs none in Homo sapiens
|
|
|
testosterone
vs placebo in Homo sapiens
|
|
|
chimpanzee diet
vs control diet in Mus musculus
|
|
|
human cafe diet
vs control diet in Mus musculus
|
|
|
human fast food diet
vs control diet in Mus musculus
|
|
|
hydrogen peroxide
vs control in Homo sapiens (4 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (4 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (1 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (8 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (8 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (1 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (12 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (12 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (24 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (24 h)
|
|
|
c-MYC knockdown
vs control in Homo sapiens (MCF-7 & breast cancer)
|
|
|
c-MYC knockdown
vs control in Homo sapiens (HeLa & cervical cancer)
|
|
|
testosterone
vs none in Mus musculus (castration & 3 d)
|
|
|
osteoarthritic ipsilateral cartilage
vs normal contralateral cartilage in Rattus norvegicus
|
|
|
osteoarthritic ipsilateral cartilage
vs sham surgery cartilage in Rattus norvegicus
|
|
|
Down syndrome
vs normal in Homo sapiens
|
|
|
benign hyperplastic enlarged lobular unit
vs normal terminal duct lobular unit in Homo sapiens
|
|
|
1,2,4-benzenetriol
vs control in Homo sapiens
|
|
|
IFNR null
vs wild_type in Mus musculus ( & influenza)
|
|
|
influenza
vs uninfected in Mus musculus ( & wild_type)
|
|
|
MAT1 ablation
vs control in Mus musculus (2 weeks)
|
|
|
MAT1 ablation
vs control in Mus musculus (4 weeks)
|
|
|
diet-induced obesity
vs reference in Rattus norvegicus
|
|
|
bicalutamide and dihydrotestoterone
vs control polyamide and dihydrotestoterone in Homo sapiens
|
|
|
dihydrotestoterone
vs control polyamide and dihydrotestoterone in Homo sapiens
|
|
|
WGWWCW polyamide and dihydrotestoterone
vs control polyamide and dihydrotestoterone in Homo sapiens
|
|
|
glucosamine
vs control in Rattus norvegicus
|
|
|
interleukin 1 beta
vs control in Rattus norvegicus
|
|
|
interleukin 1 beta and glucosamine
vs control in Rattus norvegicus
|
|
|
soluble tumor necrosis factor alpha
vs control in Mus musculus
|
|
|
transmembrane tumor necrosis factor alpha
vs control in Mus musculus
|
|
|
aldosterone-producing adenoma
vs reference in Homo sapiens
|
|
|
dinitrofluorobenzene
vs control in Mus musculus (Cnr1 -/- /Cnr2 -/-)
|
|
|
Cnr1 -/- /Cnr2 -/-
vs wild_type in Mus musculus (control)
|
|
|
Cnr1 -/- /Cnr2 -/-
vs wild_type in Mus musculus (dinitrofluorobenzene)
|
|
|
dinitrofluorobenzene
vs control in Mus musculus (wild_type)
|
|
|
Aggregatibacter actinomycetemcomitans
vs uninfected in Homo sapiens
|
|
|
Porphyromonas gingivalis
vs uninfected in Homo sapiens
|
|
|
NFI-A null
vs wild_type in Mus musculus (E18)
|
|
|
NFI-A null
vs wild_type in Mus musculus (P16)
|
|
|
ataxin-7 transgene
vs wild_type in Mus musculus (9 weeks)
|
|
|
mutant ataxin-7 transgene
vs wild_type in Mus musculus (9 weeks)
|
|
|
mutant huntingtin transgene
vs wild_type in Mus musculus (9 weeks)
|
|
|
16q LOH
vs control in Homo sapiens
|
|
|
PGC-1beta mutant
vs wild_type in Mus musculus (liver)
|
|
|
PGC-1beta mutant
vs wild_type in Mus musculus (quadriceps muscle)
|
|
|
Sendai virus
vs uninfected in Mus musculus
|
|
|
PolgD257A/D257A
vs wild_type in Mus musculus
|
|
|
AM580
vs control in Homo sapiens
|
|
|
rosiglitazone
vs control in Homo sapiens
|
|
|
p38 overexpression
vs control in Rattus norvegicus
|
|
|
smoker
vs non-smoker in Homo sapiens
|
|
|
non steroidal anti-inflammatory drugs
vs none in Homo sapiens (osteoarthritis)
|
|
|
U0126
vs none in Homo sapiens (coxsackievirus B3 & 9 h)
|
|
|
coxsackievirus B3
vs uninfected in Homo sapiens (none & 9 h)
|
|
|
coxsackievirus B3
vs uninfected in Homo sapiens (none & 0 h)
|
|
|
3 h
vs 0 h in Homo sapiens (none & coxsackievirus B3)
|
|
|
9 h
vs 0 h in Homo sapiens (none & coxsackievirus B3)
|
|
|
0.5 h
vs 0 h in Homo sapiens (none & uninfected)
|
|
|
3 h
vs 0 h in Homo sapiens (none & uninfected)
|
|
|
9 h
vs 0 h in Homo sapiens (none & uninfected)
|
|
|
coxsackievirus B3
vs uninfected in Homo sapiens (none & 3 h)
|
|
|
Crohn's disease
vs normal in Homo sapiens
|
|
|
ulcerative colitis
vs normal in Homo sapiens
|
|
|
CFTR-
vs wild_type in Mus musculus (female & B6)
|
|
|
CFTR-
vs wild_type in Mus musculus (female & BALB)
|
|
|
CFTR-
vs wild_type in Mus musculus (male & BALB)
|
|
|
1 h
vs 0 h in Homo sapiens
|
|
|
3 h
vs 0 h in Homo sapiens
|
|
|
7 d
vs 0 h in Homo sapiens
|
|
|
9 h
vs 0 h in Homo sapiens
|
|
|
Prx1Cre/+;PORlox/lox
vs wild_type in Mus musculus
|
|
|
spinal nerve transection
vs sham surgery in Rattus norvegicus
|
|
|
IDMB
vs none in Mus musculus
|
|
|
Down syndrome
vs normal in Mus musculus
|
|
|
Down syndrome
vs normal in Mus musculus
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (control - PBS)
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (HDM allergen)
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (control - PBS)
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (HDM allergen)
|
|
|
HIF-1 alpha null
vs wild_type in Mus musculus (hypoxia)
|
|
|
pauciarticular rheumatoid arthritis
vs normal in Homo sapiens (peripheral blood)
|
|
|
polyarticular rheumatoid arthritis
vs normal in Homo sapiens (peripheral blood)
|
|
|
spondyloarthropathy
vs normal in Homo sapiens (peripheral blood)
|
|
|
AKT transgenic
vs wild_type in Mus musculus (placebo & 48 h)
|
|
|
AKT transgenic
vs wild_type in Mus musculus (RAD001 & 48 h)
|
|
|
RAD001
vs placebo in Mus musculus (wild_type & 48 h)
|
|
|
RAD001
vs placebo in Mus musculus (AKT transgenic & 12 h)
|
|
|
AKT transgenic
vs wild_type in Mus musculus (placebo & 12 h)
|
|
|
AKT transgenic
vs wild_type in Mus musculus (RAD001 & 12 h)
|
|
|
RAD001
vs placebo in Mus musculus (wild_type & 12 h)
|
|
|
RAD001
vs placebo in Mus musculus (AKT transgenic & 48 h)
|
|
|
retinoic acid
vs control in Mus musculus
|
|
|
trichostatin A
vs control in Mus musculus
|
|
|
lymphotox beta
vs none in Homo sapiens (T84)
|
|
|
tumor necrosis factor alpha
vs none in Homo sapiens (Caco-2)
|
|
|
tumor necrosis factor alpha
vs none in Homo sapiens (T84)
|
|
|
flagellin
vs none in Homo sapiens (Caco-2)
|
|
|
flagellin
vs none in Homo sapiens (T84)
|
|
|
lymphotox beta
vs none in Homo sapiens (Caco-2)
|
|
|
NF1+/-
vs wild_type in Mus musculus (10 days)
|
|
|
NF1+/-
vs wild_type in Mus musculus (15 days)
|
|
|
neocarzinostatin
vs none in Homo sapiens (p53 knockdown)
|
|
|
neocarzinostatin
vs none in Homo sapiens (RelA knockdown)
|
|
|
neocarzinostatin
vs none in Homo sapiens (uninfected control)
|
|
|
neocarzinostatin
vs none in Homo sapiens (ATM knockdown)
|
|
|
neocarzinostatin
vs none in Homo sapiens (LacZ control)
|
|
|
granulocyte-colony stimulating factor
vs none in Homo sapiens
|
|
|
starved
vs control in Mus musculus
|
|
|
preconditioning seizure
vs control in Rattus norvegicus (granule cell & dentate gyrus)
|
|
|
preconditioning seizure
vs control in Rattus norvegicus (pyramidal neuron & hippocampus CA1)
|
|
|
preconditioning seizure
vs control in Rattus norvegicus (pyramidal neuron & hippocampus CA3)
|
|
|
hepatitis C virus core protein
vs control in Homo sapiens
|
|
|
CHOP-/-
vs wild_type in Mus musculus (none & 0 mg/ml & 0 h)
|
|
|
CHOP-/-
vs wild_type in Mus musculus (tunicamycin & 2 mg/ml & 4 h)
|
|
|
CHOP-/-
vs wild_type in Mus musculus (tunicamycin & 2 mg/ml & 8 h)
|
|
|
IL-21
vs control in Mus musculus
|
|
|
IL-15
vs control in Mus musculus
|
|
|
IL-15 and IL-21
vs control in Mus musculus
|
|
|
C/EBP epsilon
vs empty vector in Mus musculus
|
|
|
C/EBP alpha
vs empty vector in Mus musculus
|
|
|
C/EBP beta
vs empty vector in Mus musculus
|
|
|
C/EBP delta
vs empty vector in Mus musculus
|
|
|
apoE(-/-)
vs wild_type in Mus musculus
|
|
|
Hoxc13 overexpressing transgenic
vs wild_type in Mus musculus
|
|
|
mild cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
severe cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
mild cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
severe cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
actinic keratosis
vs normal in Homo sapiens
|
|
|
squamous cell carcinoma
vs normal in Homo sapiens
|
|
|
AIRE -/-
vs control in Mus musculus
|
|
|
high potassium
vs control in Homo sapiens
|
|
|
thapsigargin
vs control in Homo sapiens
|
|
|
0.25 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
0.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
2 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
4 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
7 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
9 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
14 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
0.25 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
0.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
2 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
4 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
7 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
9 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
14 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
motexafin gadolinium
vs control in Homo sapiens (0 uM zinc)
|
|
|
12 h
vs 0 h in Homo sapiens (control)
|
|
|
IL-13
vs control in Homo sapiens (12 h)
|
|
|
Hnf4a null
vs wild_type in Mus musculus
|
|
|
Pit-1 mutation (Snell)
vs wild_type in Mus musculus (6 months)
|
|
|
Pit-1 mutation (Snell)
vs wild_type in Mus musculus (22 months)
|
|
|
adenoviral vector
vs none in Mus musculus
|
|
|
adenoviral vector
vs none in Mus musculus
|
|
|
ultrafine particles
vs control in Homo sapiens
|
|
|
pancreatic ductal adenocarcinoma
vs normal in Homo sapiens ( & epithelial cell)
|
|
|
336 h
vs 0 h in Mus musculus
|
|
|
6 h
vs 0 h in Mus musculus
|
|
|
12 h
vs 0 h in Mus musculus
|
|
|
18 h
vs 0 h in Mus musculus
|
|
|
24 h
vs 0 h in Mus musculus
|
|
|
36 h
vs 0 h in Mus musculus
|
|
|
48 h
vs 0 h in Mus musculus
|
|
|
96 h
vs 0 h in Mus musculus
|
|
|
168 h
vs 0 h in Mus musculus
|
|
|
216 h
vs 0 h in Mus musculus
|
|
|
336 h
vs 0 h in Mus musculus
|
|
|
6 h
vs 0 h in Mus musculus
|
|
|
12 h
vs 0 h in Mus musculus
|
|
|
18 h
vs 0 h in Mus musculus
|
|
|
24 h
vs 0 h in Mus musculus
|
|
|
36 h
vs 0 h in Mus musculus
|
|
|
48 h
vs 0 h in Mus musculus
|
|
|
96 h
vs 0 h in Mus musculus
|
|
|
168 h
vs 0 h in Mus musculus
|
|
|
216 h
vs 0 h in Mus musculus
|
|
|
Rpe65 -/-
vs wild_type in Mus musculus (2 months)
|
|
|
Rpe65 -/-
vs wild_type in Mus musculus (4 months)
|
|
|
Rpe65 -/-
vs wild_type in Mus musculus (6 months)
|
|
|
leptin
vs control in Mus musculus
|
|
|
SOD1 mutant
vs control in Mus musculus (6 weeks & oculomotor nucleus)
|
|
|
SOD1 mutant
vs control in Mus musculus (6 weeks & spinal cord)
|
|
|
R6/1 transgenic
vs wild_type in Mus musculus (18 weeks)
|
|
|
R6/1 transgenic
vs wild_type in Mus musculus (27 weeks)
|
|
|
HIV encephalitis
vs control in Homo sapiens
|
|
|
neurofibriallary tangle
vs normal in Homo sapiens
|
|
|
schizophrenia
vs normal in Homo sapiens
|
|
|
clozapine
vs control in Mus musculus
|
|
|
haloperidol
vs control in Mus musculus
|
|
|
dehydration
vs control in Rattus norvegicus (neurointermediate lobe)
|
|
|
dehydration
vs control in Rattus norvegicus (paraventricular nucleus)
|
|
|
dehydration
vs control in Rattus norvegicus (supraoptic nucleus)
|
|
|
alpha-tocopherol
vs none in Mus musculus (5 months)
|
|
|
alpha-tocopherol + gamma-tocopherol
vs none in Mus musculus (5 months)
|
|
|
Alpha7 L250T heterozygous
vs wild_type in Mus musculus (nicotine)
|
|
|
Alpha7 nAChR subunit L250T heterozygous
vs wild_type in Mus musculus (none)
|
|
|
nicotine
vs none in Mus musculus (Beta4 nAChR subunit null)
|
|
|
Beta4 nAChR subunit null
vs wild_type in Mus musculus (nicotine)
|
|
|
Beta4 nAChR subunit null
vs wild_type in Mus musculus (none)
|
|
|
nicotine
vs none in Mus musculus (wild_type)
|
|
E-GEOD-1008
Transcription profiling of mouse extraocular muscle, comparison of wild type and mdx mice, 14 to 112 Days
|
|
|
mdx
vs wild_type in Mus musculus (P14)
|
|
|
mdx
vs wild_type in Mus musculus (P28)
|
|
|
mdx
vs wild_type in Mus musculus (P112)
|
|
|
E-GEOD-1009
Transcription profiling of glomeruli from human kidneys with diabetic nephropathy
|
|
|
diabetic nephropathy
vs normal in Homo sapiens
|
|
|
E-GEOD-1010
Transcription profiling of human lymphoblastic cells from familial combined hyperlipemia patients
|
|
|
familial combined hyperlipidemia
vs normal in Homo sapiens
|
|
|
E-GEOD-10211
Transcription profiling of mouse cultured airway Epithelial Cell Response to Sendai virus infection
|
|
|
Sendai virus
vs uninfected in Mus musculus
|
|
|
E-GEOD-1025
Transcription profiling of mouse hindlimb muscle, comparison of wild type and mdx mice, 7 to 112 Day
|
|
|
mdx
vs wild_type in Mus musculus (P28)
|
|
|
mdx
vs wild_type in Mus musculus (P56)
|
|
|
mdx
vs wild_type in Mus musculus (P112)
|
|
|
mdx
vs wild_type in Mus musculus (P14)
|
|
|
mdx
vs wild_type in Mus musculus (P23)
|
|
|
E-GEOD-1026
Transcription profiling of mouse diaphram, comparison of wild type and mdx mice, 7 to 112 days
|
|
|
mdx
vs wild_type in Mus musculus (P28)
|
|
|
mdx
vs wild_type in Mus musculus (P56)
|
|
|
mdx
vs wild_type in Mus musculus (P112)
|
|
|
mdx
vs wild_type in Mus musculus (P14)
|
|
|
mdx
vs wild_type in Mus musculus (P23)
|
|
|
E-GEOD-1093
Transcription profiling of mouse liver to understand the regulation of hepatic gene expression by dwarfism and caloric restriction
|
|
|
caloric restriction
vs control diet in Mus musculus (DF)
|
|
|
caloric restriction
vs control diet in Mus musculus (NL)
|
|
|
E-GEOD-1122
Transcription profiling of human lung tissue from emphysema and control patients
|
|
|
alpha-1 antitrypsin deficiency-related emphysema
vs normal in Homo sapiens
|
|
|
emphysema
vs normal in Homo sapiens
|
|
|
E-GEOD-1123
Transcription profiling of mouse C3H10T1/2 cells stimulated to differentiate using IDMB to investigate adipogenesis
|
|
|
IDMB
vs none in Mus musculus
|
|
|
E-GEOD-1124
Transcription profiling of whole blood cells from healthy African children and those with uncomplicated malaria or severe malarial anemia
|
|
|
severe malarial anaemia
vs normal in Homo sapiens
|
|
|
uncomplicated malaria
vs normal in Homo sapiens
|
|
|
E-GEOD-1145
Transcription profiling of human heart muscle from cardiomyopathy patients
|
|
|
aortic stenosis
vs normal in Homo sapiens
|
|
|
congestive cardiomyopathy
vs normal in Homo sapiens
|
|
|
hypertrophic cardiomyopathy
vs normal in Homo sapiens
|
|
|
idiopathic cardiomyopathy
vs normal in Homo sapiens
|
|
|
idiopathic dilated cardiomyopathy
vs normal in Homo sapiens
|
|
|
ischemic cardiomyopathy
vs normal in Homo sapiens
|
|
|
post-partum cardiomyopathy
vs normal in Homo sapiens
|
|
|
viral cardiomyopathy
vs normal in Homo sapiens
|
|
|
familial cardiomyopathy
vs normal in Homo sapiens
|
|
|
E-GEOD-1155
Transcription profiling of rat brain hippocampi of animals fed the ketogenic diet (KD) to provide insight into the anticonvulsant action of KD
|
|
|
ketogenic diet
vs control diet in Rattus norvegicus
|
|
|
E-GEOD-1156
Transcription profiling of rat hippocampi from animals at postnatal day 15 examined at various time points up to 240 hours following kainite treatment to provide insight into molecular effects of early childhood convulsions
|
|
|
kainate
vs control in Rattus norvegicus (6 h)
|
|
|
kainate
vs control in Rattus norvegicus (24 h)
|
|
|
kainate
vs control in Rattus norvegicus (1 h)
|
|
|
kainate
vs control in Rattus norvegicus (72 h)
|
|
|
kainate
vs control in Rattus norvegicus (240 h)
|
|
|
E-GEOD-128
Transcription profiling of retina from Rp1-/- knockout vs littermate mice
|
|
|
RP1 knockout
vs wild_type in Mus musculus (10 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (14 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (7 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (18 d)
|
|
|
RP1 knockout
vs wild_type in Mus musculus (21 d)
|
|
|
E-GEOD-1294
Transcription profiling of Ts1Cje mouse model for Down syndrome reveals dosage dependent overexpression in the trisomic region
|
|
|
Down syndrome
vs normal in Mus musculus
|
|
|
Down syndrome
vs normal in Mus musculus
|
|
|
E-GEOD-1295
Transcription profiling time course of human skeletal muscle samples from metabolic syndrome patients following defined exercise (STRRIDE study)
|
|
|
1 d
vs 0 in Homo sapiens (female)
|
|
|
3 d
vs 0 in Homo sapiens (female)
|
|
|
14 d
vs 0 in Homo sapiens (female)
|
|
|
1 d
vs 0 in Homo sapiens (male)
|
|
|
3 d
vs 0 in Homo sapiens (male)
|
|
|
14 d
vs 0 in Homo sapiens (male)
|
|
|
1 d
vs 0 in Homo sapiens (male)
|
|
|
E-GEOD-1301
Transcription profiling of wild type and IL13 knock out mice treated with allergen vs. control to investigate the IL13 role in allergic asthma
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (control - PBS)
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (HDM allergen)
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (control - PBS)
|
|
|
IL-13 knockout
vs wild_type in Mus musculus (HDM allergen)
|
|
|
E-GEOD-1321
Transcription profiling of mouse wild type and HIF-1a null hepatocyte cultures under short-term hypoxic conditions vs controls
|
|
|
HIF-1 alpha null
vs wild_type in Mus musculus (hypoxia)
|
|
|
E-GEOD-1402
Transcription profiling of human mononuclear cells from juvenile arthritis and spondyloarthropathy patients
|
|
|
pauciarticular rheumatoid arthritis
vs normal in Homo sapiens (peripheral blood)
|
|
|
polyarticular rheumatoid arthritis
vs normal in Homo sapiens (peripheral blood)
|
|
|
spondyloarthropathy
vs normal in Homo sapiens (peripheral blood)
|
|
|
E-GEOD-1413
Transcription profiling of mouse prostate from AKT transgenic or wild type littermate controls treated with RAD001 (MTOR inhibition) or placebo reveals mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways reveals
|
|
|
AKT transgenic
vs wild_type in Mus musculus (placebo & 48 h)
|
|
|
AKT transgenic
vs wild_type in Mus musculus (RAD001 & 48 h)
|
|
|
RAD001
vs placebo in Mus musculus (wild_type & 48 h)
|
|
|
RAD001
vs placebo in Mus musculus (AKT transgenic & 12 h)
|
|
|
AKT transgenic
vs wild_type in Mus musculus (placebo & 12 h)
|
|
|
AKT transgenic
vs wild_type in Mus musculus (RAD001 & 12 h)
|
|
|
RAD001
vs placebo in Mus musculus (wild_type & 12 h)
|
|
|
RAD001
vs placebo in Mus musculus (AKT transgenic & 48 h)
|
|
|
E-GEOD-1417
Transcription profiling of human Hela cells treated with the topoisomerase poison camptothecin
|
|
|
camptothecin
vs none in Homo sapiens
|
|
|
E-GEOD-1418
Transcription profiling of purified human CD34+ cells from patients treated with imatinib, and those from healthy donors
|
|
|
imatinib
vs none in Homo sapiens
|
|
|
E-GEOD-1437
Transcription profiling of mouse F9 embryonal carcinoma cells exposed to differentiating agents (retinoic acid or trichostatin A) vs controls
|
|
|
retinoic acid
vs control in Mus musculus
|
|
|
trichostatin A
vs control in Mus musculus
|
|
|
E-GEOD-1472
Transcription profiling of mouse extraocular and hindlimb muscle to determine gene expression changes in extraocular and hindlimb (gastrocnemius/soleus) of mdx (dystrophin-deficient) mice at postnatal day 56
|
|
|
mdx
vs wild_type in Mus musculus (extraocular muscle)
|
|
|
mdx
vs wild_type in Mus musculus (gastrocnemius and soleus muscle)
|
|
|
E-GEOD-1474
Transcription profiling of Caco-2 and T84 human cell lines treated with flagellin, lymphotox beta or TNF alpha
|
|
|
lymphotox beta
vs none in Homo sapiens (T84)
|
|
|
tumor necrosis factor alpha
vs none in Homo sapiens (Caco-2)
|
|
|
tumor necrosis factor alpha
vs none in Homo sapiens (T84)
|
|
|
flagellin
vs none in Homo sapiens (Caco-2)
|
|
|
flagellin
vs none in Homo sapiens (T84)
|
|
|
lymphotox beta
vs none in Homo sapiens (Caco-2)
|
|
|
E-GEOD-1482
Transcription profiling of mouse NF+/- and control samples to determine the molecular basis of the neurodevelopmental changes that result from the primary gene mutation
|
|
|
NF1+/-
vs wild_type in Mus musculus (10 days)
|
|
|
NF1+/-
vs wild_type in Mus musculus (15 days)
|
|
|
E-GEOD-1551
Transcription profiling of human muscle samples from normal and dermatomyositis patients
|
|
|
dermatomyositis
vs normal in Homo sapiens
|
|
|
E-GEOD-1563
Transcription profiling of human kidney and peripheral blood lymphocytes from kidney transplant patients
|
|
|
acute rejection
vs normal donor in Homo sapiens (peripheral blood)
|
|
|
renal dysfunction without rejection
vs normal donor in Homo sapiens (peripheral blood)
|
|
|
well-functioning transplant
vs normal donor in Homo sapiens (peripheral blood)
|
|
|
acute rejection
vs normal donor in Homo sapiens (kidney)
|
|
|
renal dysfunction without rejection
vs normal donor in Homo sapiens (kidney)
|
|
|
well-functioning transplant
vs normal donor in Homo sapiens (kidney)
|
|
|
E-GEOD-1579
Transcription profiling of mouse epidermis to investigate the differential regulation of RNA in skin from 7 week old female deltaNB-cateninER transgenic mice following 0, 1, or 7 days B-catenin activation in the epidermis
|
|
|
1 d
vs 0 in Mus musculus (wild_type)
|
|
|
K14deltaNB-cateninER
vs wild_type in Mus musculus (1 d)
|
|
|
E-GEOD-1588
Transcription profiling of mouse murine dorsal neural tube bisected along the midline with one half from each embryo used for control and the other half treated with 10-6M RA dissolved in ethanol for 6, 12, 24 or 48 h
|
|
|
retinoic acid
vs none in Mus musculus (48 h)
|
|
|
retinoic acid
vs none in Mus musculus (6 h)
|
|
|
retinoic acid
vs none in Mus musculus (12 h)
|
|
|
E-GEOD-1600
Transcription profiling of livers from 74-day old male rats fed vitamin A sufficient or vitamin A deficient diet for 53 days
|
|
|
vitamin A deficient diet
vs control diet in Rattus norvegicus
|
|
|
E-GEOD-1615
Transcription profiling of human theca cells from women with polycystic ovary syndrome and normal theca cells treated with valproate
|
|
|
valproic acid
vs none in Homo sapiens (normal)
|
|
|
polycystic ovary syndrome
vs normal in Homo sapiens (none)
|
|
|
valproic acid
vs none in Homo sapiens (normal)
|
|
|
polycystic ovary syndrome
vs normal in Homo sapiens (none)
|
|
|
E-GEOD-1621
Transcription profiling of mouse gene expression after transverse aortic constriction in mice: comparison of TAC vs. sham group at 48 hours, 10 days, and 3 weeks to identify the differential expression of genes
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (2 d)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (10 d)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (21 d)
|
|
|
E-GEOD-1676
RNAi knock down of ATM, p53 Rel_A subunit of NFkB or LacZ in human HEK293 cells treated with the radiomimetic drug NCS
|
|
|
neocarzinostatin
vs none in Homo sapiens (p53 knockdown)
|
|
|
neocarzinostatin
vs none in Homo sapiens (RelA knockdown)
|
|
|
neocarzinostatin
vs none in Homo sapiens (uninfected control)
|
|
|
neocarzinostatin
vs none in Homo sapiens (ATM knockdown)
|
|
|
neocarzinostatin
vs none in Homo sapiens (LacZ control)
|
|
|
E-GEOD-1719
Transcription profiling of human fibroblasts from subjects with age-related macular degeneration
|
|
|
age-related macular degeneration
vs normal in Homo sapiens
|
|
|
E-GEOD-1724
Transcription profiling of human lung fibroblasts isolated from pulmonary fibrosis patients and treated with TGF beta
|
|
|
transforming growth factor beta
vs none in Homo sapiens (idiopathic pulmonary fibrosis)
|
|
|
idiopathic pulmonary fibrosis
vs normal in Homo sapiens (none)
|
|
|
idiopathic pulmonary fibrosis
vs normal in Homo sapiens (transforming growth factor beta)
|
|
|
transforming growth factor beta
vs none in Homo sapiens (normal)
|
|
|
scleroderma-associated pulmonary fibrosis
vs normal in Homo sapiens (none)
|
|
|
scleroderma-associated pulmonary fibrosis
vs normal in Homo sapiens (transforming growth factor beta)
|
|
|
transforming growth factor beta
vs none in Homo sapiens (scleroderma-associated pulmonary fibrosis)
|
|
|
E-GEOD-1739
Transcription profiling of blood samples from human patients with severe acute respiratory syndrome (SARS)
|
|
|
severe acute respiratory syndrome
vs normal in Homo sapiens
|
|
|
E-GEOD-1740
Transcription profiling of the Type I interferon response of human blood monocytes primed with Type II interferon
|
|
|
interferon alpha
vs none in Homo sapiens (none)
|
|
|
primed with interferon gamma
vs none in Homo sapiens (interferon alpha)
|
|
|
primed with interferon gamma
vs none in Homo sapiens (none)
|
|
|
interferon alpha
vs none in Homo sapiens (primed with interferon gamma)
|
|
|
E-GEOD-1746
Transcription profiling of human CD14 cells from peripheral blood and G-CSF-mobilized peripheral blood
|
|
|
granulocyte-colony stimulating factor
vs none in Homo sapiens
|
|
|
E-GEOD-1776
Transcription profiling of mouse control and starved myotubes
|
|
|
starved
vs control in Mus musculus
|
|
|
E-GEOD-1781
Transcription profiling of Rattus norvegicus liver samples from individuals subjected to burn injury or cecal ligation and puncture
|
|
|
burn sepsis
vs normal in Rattus norvegicus
|
|
|
sepsis
vs normal in Rattus norvegicus
|
|
|
E-GEOD-1791
Transcription profiling of mouse D10.G4.1 T-cells treated with neuromedin U for different length of time to study the effect of neuromedin on gene expression in T cells.
|
|
|
neuromedin U
vs none in Mus musculus (6 h)
|
|
|
neuromedin U
vs none in Mus musculus (12 h)
|
|
|
neuromedin U
vs none in Mus musculus (0.75 h)
|
|
|
neuromedin U
vs none in Mus musculus (3 h)
|
|
|
E-GEOD-1801
Transcription profiling of human hematopoietic stem cells engrafted into fetal goats
|
|
|
human stem cell engraftment
vs none in Homo sapiens (Capra hircus & liver)
|
|
|
E-GEOD-1815
Transcription profiling of human bronchial epithelial cells treated with interferon gamma and/or dexamethasone
|
|
|
dexamethasone
vs none in Homo sapiens (8 h)
|
|
|
interferon gamma
vs none in Homo sapiens (8 h)
|
|
|
dexamethasone
vs none in Homo sapiens (24 h)
|
|
|
interferon gamma
vs none in Homo sapiens (24 h)
|
|
|
E-GEOD-1822
Transcription profiling of human HEK293 cells transfected with EWS-FLI1 (Ewing sarcoma family fusion gene)
|
|
|
EWS-FL1 transfected
vs mock transfected in Homo sapiens
|
|
|
E-GEOD-1833
Transcription profiling of hippocampi of rats that were injected with kainic acid at postnatal day (P) 20 to induce early-life seizures and then housed in an enriched environment until P30
|
|
|
environmental enrichment
vs control in Rattus norvegicus (kainic acid & early-life seizures)
|
|
|
environmental enrichment
vs control in Rattus norvegicus (control & reference)
|
|
|
E-GEOD-1843
Transcription profiling of liver endothelial cells in cirrhotic rats
|
|
|
cirrhosis
vs normal in Rattus norvegicus
|
|
|
E-GEOD-1869
Transcription profiling of human hearts exhibiting ischemic and nonischemic cardiomyopathy
|
|
|
ischemic cardiomyopathy
vs normal in Homo sapiens
|
|
|
non-ischemic cardiomyopathy
vs normal in Homo sapiens
|
|
|
E-GEOD-1923
Transcription profiling of human U87 wild type, neo-resistant and PDGF-A dominant negative U87 gliobastoma cells to identify PDGF-dependent patterns of gene expression
|
|
|
neo-resistant
vs wild_type in Homo sapiens (none)
|
|
|
platelet-derived growth factor
vs none in Homo sapiens (PDGF-A dominant-negative)
|
|
|
PDGF-A dominant-negative
vs wild_type in Homo sapiens (none)
|
|
|
E-GEOD-1947
Transcription profiling of mouse at ages P4 and P60 in sciatic nerve of wild type and with peripheral neuropathies to study disease mechanisms in peripheral neuropathies due to altered Pmp22 gene dosage or a Pmp22 point mutation
|
|
|
Pmp22-/-
vs wild_type in Mus musculus (B cell & P4)
|
|
|
Trembler
vs wild_type in Mus musculus (B cell & P4)
|
|
|
E-GEOD-1978
Transcription profiling of primary rat hippocampal culture cells overexpressing an activated form of calcineurin
|
|
|
activated calcineurin
vs control in Rattus norvegicus
|
|
|
lacZ
vs control in Rattus norvegicus
|
|
|
E-GEOD-1988
Transcription profiling of mouse left ventricle from male (-/-) (n=3) and (+/+) (n=4) at the age of 21M to do exercise and transcriptional analysis in male eNOS Knockout Mice
|
|
|
eNOS knockout
vs wild_type in Mus musculus
|
|
|
E-GEOD-1994
Transcription profiling of Sprague Dawley rat brain hippocampal CA1 and CA3 neurons subjected to brief preconditioning seizures
|
|
|
preconditioning seizure
vs control in Rattus norvegicus (granule cell & dentate gyrus)
|
|
|
preconditioning seizure
vs control in Rattus norvegicus (pyramidal neuron & hippocampus CA1)
|
|
|
preconditioning seizure
vs control in Rattus norvegicus (pyramidal neuron & hippocampus CA3)
|
|
|
E-GEOD-1999
Transcription profiling of mouse treated with erythropoietin(EPO) and vehicle (VEH) after hypoxic-ischemic (HI) injury to gain insight into the mechanisms underlying the neuroprotective effects of EPO
|
|
|
erythropoietin
vs none in Mus musculus (hypoxic-ischemic injury)
|
|
|
hypoxic-ischemic injury
vs none in Mus musculus (none)
|
|
|
E-GEOD-2006
Transcription profiling of human platelets from patients with essential thrombocythemia
|
|
|
essential thrombocythemia
vs normal in Homo sapiens (platelet)
|
|
|
E-GEOD-2059
Transcription profiling of mouse na've CD8+ T-cells vs. control mouse total RNA treated with IL-15 and/or IL21 vs controls to investigate regulation of CD8 cells
|
|
|
IL-21
vs control in Mus musculus
|
|
|
IL-15
vs control in Mus musculus
|
|
|
IL-15 and IL-21
vs control in Mus musculus
|
|
|
E-GEOD-2067
Transcription profiling of human HepG2 cell lines reveals hepatitis C virus core proten induces expression of genes regulating immune invasion and anti-apoptosis
|
|
|
hepatitis C virus core protein
vs control in Homo sapiens
|
|
|
E-GEOD-2082
Transcription profiling of mouse embryonic fibroblasts (MEF) from wild type vs CHOP-/- genotypes treated with tunicamycin reveals CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum
|
|
|
CHOP-/-
vs wild_type in Mus musculus (none & 0 mg/ml & 0 h)
|
|
|
CHOP-/-
vs wild_type in Mus musculus (tunicamycin & 2 mg/ml & 4 h)
|
|
|
CHOP-/-
vs wild_type in Mus musculus (tunicamycin & 2 mg/ml & 8 h)
|
|
|
E-GEOD-2111
Transcription profiling of human bronchial epithelial cells treated with vehicle (control), VOSO4 (V, 50 uM) or ZnSO4 (Zn, 50 uM) for 4 hours.
|
|
|
vanadium
vs control in Homo sapiens
|
|
|
zinc
vs control in Homo sapiens
|
|
|
E-GEOD-2120
Transcription profiling of mouse 3T3-F442A adipocytes treated with or without growth hormone (GH) to identify a mechanism for regulation of activating transcription factor 3 by GH
|
|
|
growth hormone
vs control in Mus musculus (0.5 h)
|
|
|
growth hormone
vs control in Mus musculus (4 h)
|
|
|
growth hormone
vs control in Mus musculus (48 h)
|
|
|
E-GEOD-2152
Transcription profiling of human uterine fibroids mith mutated or wild type fumarate hydratase gene
|
|
|
mutant fumarate hydratase
vs wild_type in Homo sapiens
|
|
|
E-GEOD-2188
Transcription profiling of mouse fibroblast cells transfected with zinc-inducible C/EBP expression vectors identifies Per2 as a gene implicated in myeloid leukemia
|
|
|
C/EBP epsilon
vs empty vector in Mus musculus
|
|
|
C/EBP alpha
vs empty vector in Mus musculus
|
|
|
C/EBP beta
vs empty vector in Mus musculus
|
|
|
C/EBP delta
vs empty vector in Mus musculus
|
|
|
E-GEOD-2192
Transcription profiling of NIH3T3 cells over-expressing PPARg or EBF1 to study the efficiency and kinetics of cell adipogenesis induced by PPARg and EBF1.
|
|
|
4 d
vs 0 in Mus musculus (PPARgamma2 transfection)
|
|
|
10 d
vs 0 in Mus musculus (PPARgamma2 transfection)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (2 d)
|
|
|
early B-cell factor 1 transfection
vs empty vector in Mus musculus (4 d)
|
|
|
early B-cell factor 1 transfection
vs empty vector in Mus musculus (0)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (4 d)
|
|
|
early B-cell factor 1 transfection
vs empty vector in Mus musculus (10 d)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (10 d)
|
|
|
4 d
vs 0 in Mus musculus (early B-cell factor 1 transfection)
|
|
|
10 d
vs 0 in Mus musculus (early B-cell factor 1 transfection)
|
|
|
PPARgamma2 transfection
vs empty vector in Mus musculus (0)
|
|
|
2 d
vs 0 in Mus musculus (empty vector)
|
|
|
4 d
vs 0 in Mus musculus (empty vector)
|
|
|
10 d
vs 0 in Mus musculus (empty vector)
|
|
|
2 d
vs 0 in Mus musculus (PPARgamma2 transfection)
|
|
|
E-GEOD-2198
Transcription profiling of muscles from mice with genetically modified muscle glycogen content to study the impact of glycogen content on gene expression.
|
|
|
glycogen synthase -/-
vs wild_type in Mus musculus (medial gastrocnemius)
|
|
|
GSL30
vs wild_type in Mus musculus (medial gastrocnemius)
|
|
|
glycogen synthase -/-
vs wild_type in Mus musculus (anterior tibialis)
|
|
|
glycogen synthase -/-
vs wild_type in Mus musculus (liver)
|
|
|
E-GEOD-2251
Transcription profiling of human breast cancer cells expressing ERalpha and treated with 17beta-estradiol
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERalpha expression)
|
|
|
17beta-estradiol
vs none in Homo sapiens (lacZ expression)
|
|
|
E-GEOD-2275
Transcription profiling of normal and tumorigenic Rattus norvegicus cell lines grown under normal and arginine deprivation conditions
|
|
|
arginine deprivation
vs normal in Rattus norvegicus (normal)
|
|
|
tumorigenic
vs normal in Rattus norvegicus (arginine deprivation)
|
|
|
tumorigenic
vs normal in Rattus norvegicus (normal)
|
|
|
arginine deprivation
vs normal in Rattus norvegicus (tumorigenic)
|
|
|
E-GEOD-2292
Transcription profiling of human U2OS cells expressing estrogen receptor alpha and beta heterodimers and treated with 17beta-estradiol or 4OH-tamoxifen
|
|
|
4OH-tamoxifen
vs none in Homo sapiens (ERalpha transfected)
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERalpha transfected)
|
|
|
4OH-tamoxifen
vs none in Homo sapiens (ERbeta transfected)
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERbeta transfected)
|
|
|
4OH-tamoxifen
vs none in Homo sapiens (ERalpha/beta transfected)
|
|
|
17beta-estradiol
vs none in Homo sapiens (ERalpha/beta transfected)
|
|
|
E-GEOD-2331
Transcription profiling of mammary glands from rats treated with RXR or untreated, to compare results from individual and pooled samples
|
|
|
LG100268
vs none in Rattus norvegicus (individual sample)
|
|
|
LG100268
vs none in Rattus norvegicus (three pooled samples)
|
|
|
LG100268
vs none in Rattus norvegicus (two pooled samples)
|
|
|
E-GEOD-2354
Transcription profiling of Rattus norvegicus small intestine and colon samples treated with amoxicillin
|
|
|
amoxicillin
vs none in Rattus norvegicus (colon & 21 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (distal small intestine & 21 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (proximal small intestine & 21 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (distal small intestine & 17 d)
|
|
|
amoxicillin
vs none in Rattus norvegicus (proximal small intestine & 17 d)
|
|
|
E-GEOD-2372
Transcription profiling of aortae from 32 week old apoE and wild type mice
|
|
|
apoE(-/-)
vs wild_type in Mus musculus
|
|
|
E-GEOD-2374
Transcription profiling of skin from wild type and Hoxc13 transgenic mice to investigate their propensity to develop severe hair growth defects and alopecia
|
|
|
Hoxc13 overexpressing transgenic
vs wild_type in Mus musculus
|
|
|
E-GEOD-2378
Transcription profiling of human optic nerve head astrocytes from normal and glaucoma patients
|
|
|
glaucoma
vs normal in Homo sapiens
|
|
|
E-GEOD-2392
Transcription profiling of mice and rats at different time points after moderate levels of brain injury to identify candidate molecular pathways induced by brain injury.
|
|
|
lateral fluid percussion-induced injury
vs sham in Rattus norvegicus (Rattus norvegicus & 8 h)
|
|
|
0.5 h
vs 0 in Rattus norvegicus (sham & Rattus norvegicus)
|
|
|
8 h
vs 0 in Rattus norvegicus (sham & Rattus norvegicus)
|
|
|
lateral fluid percussion-induced injury
vs sham in Rattus norvegicus (Rattus norvegicus & 0.5 h)
|
|
|
E-GEOD-2395
Transcription profiling of nasal epithelium from CF patients with mild and severe cystic fibrosis lung disease to identify candidate genes that influence the severity of pulmonary disease and to identify genes indicative of CF disease progression
|
|
|
mild cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
severe cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
mild cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
severe cystic fibrosis, pulmonary disease
vs normal in Homo sapiens
|
|
|
E-GEOD-2401
Transcription profiling of Rattus norvegicus kidney samples from normal and acute hypotensive animals
|
|
|
acute hypotension
vs normal in Rattus norvegicus
|
|
|
E-GEOD-2405
Transcription profiling time course of the human polymorphonuclear leukocyte response to exposure to Anaplasma phagocytophilum or Staphylococcus aureus
|
|
|
3 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
6 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
Anaplasma phagocytophilum
vs uninfected in Homo sapiens (24 h)
|
|
|
heat-killed Anaplasma phagocytophilum
vs uninfected in Homo sapiens (24 h)
|
|
|
heat-killed HL60 cell lysate
vs uninfected in Homo sapiens (24 h)
|
|
|
9 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
HL60 cell lysate
vs uninfected in Homo sapiens (24 h)
|
|
|
Staphylococcus aureus
vs uninfected in Homo sapiens (24 h)
|
|
|
24 h
vs 0 in Homo sapiens (Anaplasma phagocytophilum)
|
|
|
E-GEOD-2413
Transcription profiling of mouse S49 cells to study the global impact of cAMP and protein kinase A on gene expression
|
|
|
Kin-
vs wild_type in Mus musculus (cAMP & 24 h)
|
|
|
Kin-
vs wild_type in Mus musculus (control & 0)
|
|
|
Kin-
vs wild_type in Mus musculus (cAMP & 2 h)
|
|
|
Kin-
vs wild_type in Mus musculus (cAMP & 6 h)
|
|
|
E-GEOD-2429
Transcription profiling of human atypical ductal hyperplasia tissue from women with or without a history of breast cancer
|
|
|
breast cancer
vs normal in Homo sapiens
|
|
|
E-GEOD-2431
Transcription profiling of livers from mice fed with different diets to Identify potential caloric restriction mimetics.
|
|
|
glipizide + metformin
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
metformin
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
rosiglitazone
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
soy isoflavone extract
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
glipizide
vs none in Mus musculus (93 kcal per wk for 8 wk)
|
|
|
E-GEOD-2437
Transcription profiling of murine olfactory epithelium during neuronal death and replacement to study adult neurogenesis in the olfactory epithelium
|
|
|
olfactory bulbectomy
vs sham surgery in Mus musculus (5 d)
|
|
|
E-GEOD-2457
Transcription profiling of Rattus norvegicus penis samples from animals with diabetes-induced erectile dysfunction
|
|
|
diabetes-induced erectile dysfunction
vs normal in Rattus norvegicus
|
|
|
E-GEOD-2459
Transcription profiling of hearts from FVB male mice subjected to cardiac pressure overload by transverse aortic constriction to study the quantitative relationships between gene expression and left ventricular hypertrophy
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (female)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (male)
|
|
|
E-GEOD-2470
Transcription profiling of tungstate-induced beta cell mass increase in Rattus norvegicus subjects with induced diabetes
|
|
|
sodium tungstate
vs none in Rattus norvegicus (diabetes mellitus)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (none)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (sodium tungstate)
|
|
|
sodium tungstate
vs none in Rattus norvegicus (normal)
|
|
|
E-GEOD-2503
Transcription profiling of human normal skin, actinic keratosis and squamous cell carcinoma
|
|
|
actinic keratosis
vs normal in Homo sapiens
|
|
|
squamous cell carcinoma
vs normal in Homo sapiens
|
|
|
E-GEOD-2504
Transcription profiling of untreated, HIV-1 vector-infected and TNFalpha-treated human Jurkat T cells
|
|
|
HIV-1 infected
vs normal in Homo sapiens (none)
|
|
|
tumor necrosis factor alpha
vs none in Homo sapiens (normal)
|
|
|
E-GEOD-2507
Transcription profiling of skeletal and cardiac muscles in dysferlin-deficient SJL/J mice and wild type mice to understand the protective mechanisms against dysferlin deficiency in cardiac muscles.
|
|
|
Dysf-/-
vs wild_type in Mus musculus (left ventricular myocardium)
|
|
|
Dysf-/-
vs wild_type in Mus musculus (skeletal muscle)
|
|
|
E-GEOD-2508
Transcription profiling of human abdominal subcutaneous adipocytes from obese and non-obese Pima Indians
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
E-GEOD-2510
Transcription profiling of cultured human preadipocytes/stromal vascular cells from obese and non-obese Pima Indians
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
obesity
vs normal in Homo sapiens (female)
|
|
|
obesity
vs normal in Homo sapiens (male)
|
|
|
E-GEOD-2514
Transcription profiling of human lung adenocarcinoma and a carcinogen-induced mouse model
|
|
|
lung adenocarcinoma
vs normal in Homo sapiens (Homo sapiens)
|
|
|
E-GEOD-2515
Transcription profiling of thymic epithelial cells from C57BL/6 and AIRE knockout mice.
|
|
|
AIRE -/-
vs control in Mus musculus
|
|
|
E-GEOD-2527
Transcription profiling of megakaryocyte cells from Gata-1 knock out mice and wild type mice to study the differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development
|
|
|
Gata-1(-/-)
vs wild_type in Mus musculus
|
|
|
E-GEOD-2549
Transcription profiling of human malignant pleural mesothelioma tumors and cell lines
|
|
|
malignant pleural mesothelioma
vs normal in Homo sapiens ( & pleura)
|
|
|
E-GEOD-2556
Transcription profiling of preadipocytes of wild type and IRS-1,IRS-2, IRS-3, IRS-4 knock out mice to reveal role of insulin receptor substrates and necdin
|
|
|
IRS-1
vs wild_type in Mus musculus
|
|
|
IRS-4
vs wild_type in Mus musculus
|
|
|
IRS-3
vs wild_type in Mus musculus
|
|
|
IRS-2
vs wild_type in Mus musculus
|
|
|
E-GEOD-2566
Transcription profiling of Rattus norvegicus muscle samples from reinnervated subjects
|
|
|
reinnervation of rat muscle
vs none in Rattus norvegicus
|
|
|
E-GEOD-2599
Transcription profiling of Rattus norvegicus spinal cord contusion 35 days after injury
|
|
|
spinal cord contusion
vs none in Rattus norvegicus
|
|
|
E-GEOD-2606
Transcription profiling of Rattus norvegicus FGFR3-K650E mutant and wild type PC12 cells
|
|
|
FGFR3-K650E
vs wild_type in Rattus norvegicus
|
|
|
E-GEOD-2624
Transcription profiling of human tetracycline-regulated cell line expressing an NF-kB inhibitor to systematically identify NF-kB dependent genes
|
|
|
doxycycline
vs none in Homo sapiens (3 h)
|
|
|
doxycycline
vs none in Homo sapiens (6 h)
|
|
|
doxycycline
vs none in Homo sapiens (0)
|
|
|
1 h
vs 0 in Homo sapiens (doxycycline)
|
|
|
3 h
vs 0 in Homo sapiens (doxycycline)
|
|
|
6 h
vs 0 in Homo sapiens (doxycycline)
|
|
|
1 h
vs 0 in Homo sapiens (none)
|
|
|
3 h
vs 0 in Homo sapiens (none)
|
|
|
6 h
vs 0 in Homo sapiens (none)
|
|
|
doxycycline
vs none in Homo sapiens (1 h)
|
|
|
E-GEOD-2636
Transcription profiling of Rattus norvegicus dorsal root ganglia from CCI and Seltzer models of neuropathic pain
|
|
|
chronic constriction
vs sham surgery in Rattus norvegicus (21 d)
|
|
|
partial sciatic nerve ligation
vs sham surgery in Rattus norvegicus (21 d)
|
|
|
E-GEOD-2649
Transcription profiling of human soluble guanylate cyclase-deficient U937 cells exposed to the nitric oxide (NO) donor S-nitrosoglutathione to provide insight into the cGMP-independent effects of NO
|
|
|
S-nitrosoglutathione plus dibutyryl cAMP
vs none in Homo sapiens (differentiated)
|
|
|
glutathione
vs none in Homo sapiens (differentiated)
|
|
|
glutathione plus dibutyryl cAMP
vs none in Homo sapiens (differentiated)
|
|
|
S-nitrosoglutathione
vs none in Homo sapiens (differentiated)
|
|
|
E-GEOD-2685
Transcription profiling of human advanced gastric cancer tissues and noncancerous gastric tissues to gain molecular understanding of carcinogenesis, progression, and diversity of gastric cancer
|
|
|
gastric cancer
vs normal in Homo sapiens
|
|
|
E-GEOD-2712
Transcription profiling of human Clear cell sarcoma of the kidney (CCSK) vs Wilms tumors (WT) and fetal kidney samples to address diagnostic challenges of CCSK
|
|
|
clear cell sarcoma of the kidney
vs normal in Homo sapiens
|
|
|
Wilms' tumor
vs normal in Homo sapiens
|
|
|
E-GEOD-2746
Transcription profiling of differentiating mouse embryonic fibroblasts generated from wild type and PKBa-/- mice to study the role of PKBa in adipose differentiation.
|
|
|
PKB alpha null
vs wild_type in Mus musculus (24 h)
|
|
|
PKB alpha null
vs wild_type in Mus musculus (48 h)
|
|
|
PKB alpha null
vs wild_type in Mus musculus (0)
|
|
|
2 h
vs 0 in Mus musculus (PKB alpha null)
|
|
|
24 h
vs 0 in Mus musculus (PKB alpha null)
|
|
|
48 h
vs 0 in Mus musculus (PKB alpha null)
|
|
|
2 h
vs 0 in Mus musculus (wild_type)
|
|
|
24 h
vs 0 in Mus musculus (wild_type)
|
|
|
48 h
vs 0 in Mus musculus (wild_type)
|
|
|
PKB alpha null
vs wild_type in Mus musculus (2 h)
|
|
|
E-GEOD-2772
Transcription profiling of parietal cells isolated from WT and Gastrin Knockout mice to identify genes responsive to gastrin.
|
|
|
gastrin-/gastrin-
vs wild_type in Mus musculus
|
|
|
E-GEOD-2779
Transcription profiling of normal v early MDS v non-MDS anemia bone marrow CD34 cells to identify biomarkers of disease
|
|
|
myelodysplastic syndrome
vs normal in Homo sapiens ( & female)
|
|
|
myelodysplastic syndrome
vs normal in Homo sapiens ( & male)
|
|
|
E-GEOD-2803
Transcription profiling of human PMNs to compare global gene expression in human neutrophils during spontaneous apoptosis with that in cells cultured with human granulocyte macrophage-colony stimulating factor
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (6 h)
|
|
|
3 h
vs 0 in Homo sapiens (none)
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (18 h)
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (24 h)
|
|
|
6 h
vs 0 in Homo sapiens (none)
|
|
|
12 h
vs 0 in Homo sapiens (none)
|
|
|
18 h
vs 0 in Homo sapiens (none)
|
|
|
24 h
vs 0 in Homo sapiens (none)
|
|
|
granulocyte macrophage-colony stimulating factor
vs none in Homo sapiens (3 h)
|
|
|
E-GEOD-2852
Transcription profiling time course of Rattus norvegicus liver and kidney samples from animals treated with ochratoxin A and controls for 7 days to 12 months
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 4 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 4 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 7 d)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 7 d)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 7 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 7 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 12 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 12 m)
|
|
|
ochratoxin
vs none in Rattus norvegicus (kidney & 21 d)
|
|
|
ochratoxin
vs none in Rattus norvegicus (liver & 21 d)
|
|
|
E-GEOD-2866
Transcription profiling of a mouse model of succinate semialdehyde dehydrogenase deficiency vs wild type litter mates reveals multiple myelin alterations
|
|
|
Aldh5a1-/-
vs wild_type in Mus musculus (cerebellum)
|
|
|
Aldh5a1-/-
vs wild_type in Mus musculus (cortex)
|
|
|
Aldh5a1-/-
vs wild_type in Mus musculus (hippocampus)
|
|
|
E-GEOD-2867
Transcription profiling of a mouse model for spinocerebellar ataxia 1 vs, wild type littermates sampled at 4 and 11 weeks
|
|
|
SCA1 model
vs wild_type in Mus musculus (cerebellum & 11 weeks)
|
|
|
E-GEOD-2869
Transcription profiling of HIPK2 dominant negative mouse mutants vs wild type littermates to identify genes regulated by HIPK2 which are likely to be involved in axon pathfinding
|
|
|
HIPK2 dominant-negative
vs wild_type in Mus musculus
|
|
|
E-GEOD-2874
Transcription profiling of rats treated with denervation vs. sham treated to identify genes with altered regulation during cortical re-organization
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (14 d)
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (28 d)
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (3)
|
|
|
partial paw denervation
vs sham denervation in Rattus norvegicus (7 d)
|
|
|
E-GEOD-2883
Transcription profilfing of human cerebrovascular smooth muscle to identify Ca2+-dependent transcription patterns
|
|
|
high potassium
vs control in Homo sapiens
|
|
|
thapsigargin
vs control in Homo sapiens
|
|
|
E-GEOD-2926
Transcription profiling of livers from SCD1 knockout and wild type mice to elucidate the molecular basis of protection against adiposity in mice lacking of stearoyl-CoA desaturase-1 function
|
|
|
SCD1 -/-
vs wild_type in Mus musculus
|
|
|
E-GEOD-2964
Transcription profiling of human B-cell lymphoma cell lines treated with motexafin gadolinium and zinc reveals induced oxidative stress responses and apoptosis
|
|
|
motexafin gadolinium
vs control in Homo sapiens (0 uM zinc)
|
|
|
E-GEOD-2972
Transcription profiling of mouse embryonic stem cells and embryoid bodies at 11 different time points to study gene function in early mouse embryonic stem cell differentiation.
|
|
|
0.25 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
0.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
2 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
4 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
7 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
9 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
14 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
0.25 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
0.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
1.5 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
2 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
4 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
7 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
9 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
14 d
vs 0 d in Mus musculus (embryoid body)
|
|
|
E-GEOD-2973
Transcript profiling of bone marrow-derived macrophages from mice of different genetic background to compare transcriptional responses to infection with Yersinia enterocolitica
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pYV) (virulent) & BALB/c)
|
|
|
interferon-gamma
vs none in Mus musculus (uninfected & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (interferon-gamma & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (interferon-gamma & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (none & C57BL/6J)
|
|
|
interferon-gamma
vs none in Mus musculus (uninfected & BALB/c)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (none & C57BL/6J)
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pTTS, pP60) (control) & C57BL/6J)
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pYV) (virulent) & C57BL/6J)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (interferon-gamma & BALB/c)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (interferon-gamma & BALB/c)
|
|
|
Yersinia enterocolitica WA(pTTS, pP60) (control)
vs uninfected in Mus musculus (none & BALB/c)
|
|
|
Yersinia enterocolitica WA(pYV) (virulent)
vs uninfected in Mus musculus (none & BALB/c)
|
|
|
interferon-gamma
vs none in Mus musculus (Yersinia enterocolitica WA(pTTS, pP60) (control) & BALB/c)
|
|
|
E-GEOD-3040
Transcription profiling of human lens epithelial cells to examine glucocorticoid induced changes
|
|
|
dexamethasone
vs none in Homo sapiens (4 h)
|
|
|
dexamethasone
vs none in Homo sapiens (16 h)
|
|
|
E-GEOD-3068
Transcription profiling of Rattus norvegicus rear leg muscle from normal and diabetic subjects treated with vanadyl sulfate
|
|
|
vanadyl sulfate
vs none in Rattus norvegicus (diabetes mellitus)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (none)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (vanadyl sulfate)
|
|
|
vanadyl sulfate
vs none in Rattus norvegicus (normal)
|
|
|
E-GEOD-3075
Transcription profiling of spinal cords from nmd mice tranplanted with ALDHhiSSClo neural stem cells to study molecular mechanism of delayed SMARD1 disease progression induced by the transplantation.
|
|
|
ALDHhiSSClo neural stem cells transplantation
vs untreated in Mus musculus (nmd)
|
|
|
nmd
vs wild_type in Mus musculus (untreated)
|
|
|
E-GEOD-3100
Transcription profiling of lung from a mouse model of cystic fibrosis fromB6 and Balb strains vs wild type littermates to determine strain specific differences
|
|
|
CFTR-
vs wild_type in Mus musculus (female & B6)
|
|
|
CFTR-
vs wild_type in Mus musculus (female & BALB)
|
|
|
CFTR-
vs wild_type in Mus musculus (male & BALB)
|
|
|
E-GEOD-3126
Transcription profiling of wild type mouse livers and livers from hepatocyte nuclear factor 4alpha deficient mice to study the role of HNF4a in hepatogenesis.
|
|
|
Hnf4a null
vs wild_type in Mus musculus
|
|
|
E-GEOD-3129
Transcription profiling of livers from aged and young Snell dwarf mice and their wild type controls to identify genetic signatures.
|
|
|
Pit-1 mutation (Snell)
vs wild_type in Mus musculus (6 months)
|
|
|
Pit-1 mutation (Snell)
vs wild_type in Mus musculus (22 months)
|
|
|
E-GEOD-3140
Transcription profiling of human adult peripheral vs cord blood mononuclear cells altered by lipopolysaccharide to understand the influence of early molecular signals on the effects of sepsis
|
|
|
lipopolysaccharide
vs none in Homo sapiens (adult)
|
|
|
E-GEOD-3167
Transcription profiling of human urinary superficial transitional cell carcinoma with surrounding carcinoma in situ (CIS) lesions, without surrounding CIS lesions, and muscle invasive carcinoma
|
|
|
carcinoma in situ lesion
vs normal in Homo sapiens (bladder)
|
|
|
muscle invasive carcinoma
vs normal in Homo sapiens (bladder)
|
|
|
superficial transitional cell carcinoma without surrounding carcinoma in situ lesion
vs normal in Homo sapiens (bladder)
|
|
|
superficial transitional cell carcinoma with surrounding carcinoma in situ lesion
vs normal in Homo sapiens (bladder)
|
|
|
E-GEOD-3172
Transcription profiling of mouse fibroblast cells infected with adenoviral vector or mock infected
|
|
|
adenoviral vector
vs none in Mus musculus
|
|
|
adenoviral vector
vs none in Mus musculus
|
|
|
E-GEOD-3173
Transcription profiling of Rattus norvegicus liver samples from animals treated with D3T (3H-1,2-dithiole-3-thione) and controls
|
|
|
3H-1,2-dithiole-3-thione
vs none in Rattus norvegicus
|
|
|
E-GEOD-3183
Transcription profiling of human bronchial cell line treated with IL-13 to better understand early cytokine-mediated mechanisms that lead to asthma
|
|
|
12 h
vs 0 h in Homo sapiens (control)
|
|
|
IL-13
vs control in Homo sapiens (12 h)
|
|
|
E-GEOD-3189
Transcription profiling of human tissue samples to identify novel genes associated with malignant melanoma but not benign melanocytic lesions
|
|
|
benign nevi
vs normal in Homo sapiens
|
|
|
malignant melanoma
vs normal in Homo sapiens
|
|
|
E-GEOD-3203
Transcription profiling of mouse influenza virus infected in wild type and mutant animals revels induced gene expression changes of regional B cells are mediated in part through type I IFN
|
|
|
IFNR null
vs wild_type in Mus musculus ( & influenza)
|
|
|
influenza
vs uninfected in Mus musculus ( & wild_type)
|
|
|
E-GEOD-3212
Transcription profiling of human alveolar macrophages from phenotypically normal smokers compared to non-smokers to identify new genes linking to early events in the molecular pathogenesis of COPD
|
|
|
smoker
vs non-smoker in Homo sapiens (alveolar macrophage & male)
|
|
|
E-GEOD-3231
Transcription profiling of mouse V6.5 embryonic stem cells versus embryoid bodies
|
|
|
336 h
vs 0 h in Mus musculus
|
|
|
6 h
vs 0 h in Mus musculus
|
|
|
12 h
vs 0 h in Mus musculus
|
|
|
18 h
vs 0 h in Mus musculus
|
|
|
24 h
vs 0 h in Mus musculus
|
|
|
36 h
vs 0 h in Mus musculus
|
|
|
48 h
vs 0 h in Mus musculus
|
|
|
96 h
vs 0 h in Mus musculus
|
|
|
168 h
vs 0 h in Mus musculus
|
|
|
216 h
vs 0 h in Mus musculus
|
|
|
336 h
vs 0 h in Mus musculus
|
|
|
6 h
vs 0 h in Mus musculus
|
|
|
12 h
vs 0 h in Mus musculus
|
|
|
18 h
vs 0 h in Mus musculus
|
|
|
24 h
vs 0 h in Mus musculus
|
|
|
36 h
vs 0 h in Mus musculus
|
|
|
48 h
vs 0 h in Mus musculus
|
|
|
96 h
vs 0 h in Mus musculus
|
|
|
168 h
vs 0 h in Mus musculus
|
|
|
216 h
vs 0 h in Mus musculus
|
|
|
E-GEOD-3249
Transcription profiling of wild type and Rpe65-/- mouse retinae to characterize gene response in Rpe65-/- mouse model of Lebers congenital amaurosis during progression of the disease.
|
|
|
Rpe65 -/-
vs wild_type in Mus musculus (2 months)
|
|
|
Rpe65 -/-
vs wild_type in Mus musculus (4 months)
|
|
|
Rpe65 -/-
vs wild_type in Mus musculus (6 months)
|
|
|
E-GEOD-3293
Transcription profiling of gallbladders from mice treated with leptin or saline to test the hypothesis that leptin would alter gallbladder gene expression
|
|
|
leptin
vs control in Mus musculus
|
|
|
E-GEOD-3311
Transcription profiling of the effect of chronic ethanol consumption on Rattus norvegicus pancreas
|
|
|
Lieber-DeCarli diet (36% calories from ethanol)
vs control diet in Rattus norvegicus
|
|
|
E-GEOD-3320
Transcription profiling of human small airway bronchial epithelium to assess gene expression in phenotypically normal smokers compared to matched non-smokers
|
|
|
smoker
vs non-smoker in Homo sapiens (male)
|
|
|
E-GEOD-3343
Transcription profiling of spinal cord and oculomotor neurons from control and SOD1 mutant mice to test the hypothesis that the oculomotor neurons are intrinsically protected in amyotrophic lateral sclerosis
|
|
|
SOD1 mutant
vs control in Mus musculus (6 weeks & oculomotor nucleus)
|
|
|
SOD1 mutant
vs control in Mus musculus (6 weeks & spinal cord)
|
|
|
E-GEOD-3365
Transcription profiling of human healthy subjects, patients with Crohn's disease, and patients with ulcerative colitis to compare peripheral blood mononuclear cells in inflammatory bowel disease
|
|
|
Crohn's disease
vs normal in Homo sapiens (female)
|
|
|
ulcerative colitis
vs normal in Homo sapiens (female)
|
|
|
Crohn's disease
vs normal in Homo sapiens (male)
|
|
|
ulcerative colitis
vs normal in Homo sapiens (male)
|
|
|
E-GEOD-3414
Transcription profiling of lungs from SCID and wild type mice infected with L3 stage infectious Nippostrongylus brasiliensis to examine the innate immune response to helminth infection in the lung.
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 3 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 4 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (uninfected & 0 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 8 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 12 d)
|
|
|
BALB/c SCID
vs wild_type in Mus musculus (Nippostrongylus brasiliensis & 2 d)
|
|
|
E-GEOD-3455
Transcription profiling of olfactory epithelium isolated from wild type and SR-A mutant mice at different time points after bilateral olfactory bulbectomy to understand the temporal gene expression patterns.
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 16 h)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 48 h)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (sham surgery & 0)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 2 h)
|
|
|
SR-A mutant
vs wild_type in Mus musculus (bilateral olfactory bulbectomy & 8 h)
|
|
|
E-GEOD-3485
RNAi knock down of LEDGF transcript from the PSIP1 gene in human 293T cells reveals a role for LEDFG/p75 in targeting HIV integration
|
|
|
LEDGF knockdown
vs control in Homo sapiens
|
|
|
E-GEOD-3489
Transcription profiling of human brain samples from HIV infected individuals with HIV encephalitis vs controls
|
|
|
HIV encephalitis
vs control in Homo sapiens
|
|
|
E-GEOD-3491
Transcription profiling of human lpshigh and lpslow individuals to reveal interindividual variability in LPS responses
|
|
|
lipopolysaccharide
vs none in Homo sapiens (low response)
|
|
|
E-GEOD-3565
Transcription profiling of spleens from dual specificity phosphatase-1 (DUSP1) deficient and wild type mice to demonstrate a specific regulatory role of DUSP1 on a subset of LPS-induced genes that control the outcome of endotoxin shock.
|
|
|
lipopolysaccharide
vs control in Mus musculus (DUSP1-/-)
|
|
|
lipopolysaccharide
vs control in Mus musculus (DUSP1+/+)
|
|
|
E-GEOD-3595
Transcription profiling of olfactory epithelia isolated from wild type and KLF7 null mice to identify potential KLF7 target genes in olfactory sensory neurons.
|
|
|
KLF7-/-
vs wild_type in Mus musculus
|
|
|
E-GEOD-361
Transcription profiling of human mammary epithelial cells transduced with either hTERT, empty LXSN vector or empty BABE vector
|
|
|
empty pBabe transduced
vs none in Homo sapiens
|
|
|
hTERT transduced
vs none in Homo sapiens
|
|
|
E-GEOD-3621
Transcription profiling of HD R6/1 transgenic mouse line brain hemispheres, time series
|
|
|
R6/1 transgenic
vs wild_type in Mus musculus (18 weeks)
|
|
|
R6/1 transgenic
vs wild_type in Mus musculus (27 weeks)
|
|
|
E-GEOD-363
Transcription profiling of livers of C57BL/6 mice and LDL receptor deficient mice fed on either low fat or high fat diet to study liver gene expression associated with diet.
|
|
|
LDLR-/-
vs wild_type in Mus musculus (high fat diet)
|
|
|
LDLR-/-
vs wild_type in Mus musculus (low fat diet)
|
|
|
E-GEOD-3634
Transcription profiling of mouse retina from an animal model of spinocerebellar ataxia (SCA)
|
|
|
ataxin-7 transgene
vs wild_type in Mus musculus (9 weeks)
|
|
|
mutant ataxin-7 transgene
vs wild_type in Mus musculus (9 weeks)
|
|
|
mutant huntingtin transgene
vs wild_type in Mus musculus (9 weeks)
|
|
|
E-GEOD-3737
Transcription profiling of human prostate cancer cells with arachidonic acid reveals induction of 11 genes that are regulated by NFkappaB
|
|
|
arachidonic acid
vs control - albumin in Homo sapiens
|
|
|
E-GEOD-3744
Transcription profiling of 47 human breast tumor cases
|
|
|
non-basal-like breast cancer
vs normal in Homo sapiens
|
|
|
sporadic basal-like breast cancer
vs normal in Homo sapiens
|
|
|
E-GEOD-3866
Transcription profiling of rat p38 MAPK overexpression in heart in vivo.
|
|
|
p38 overexpression
vs control in Rattus norvegicus
|
|
|
E-GEOD-3889
Transcription profiling of livers of stearoyl-CoA desaturase 1-deficient mice to search for gene expression changes unique to SCD1-/- mice on a very low fat, high carbohydrate diet.
|
|
|
SCD1-/-
vs wild_type in Mus musculus (control diet)
|
|
|
very low fat, high carbohydrate diet
vs control diet in Mus musculus (SCD1-/-)
|
|
|
very low fat, high carbohydrate diet
vs control diet in Mus musculus (wild_type)
|
|
|
SCD1-/-
vs wild_type in Mus musculus (very low fat, high carbohydrate diet)
|
|
|
E-GEOD-3920
Transcription profiling of human endothelial and fibroblast cells isolated from umbilical veins treated with interferons to identify genes regulated by interferons
|
|
|
interferon alpha
vs control in Homo sapiens (endothelial cell)
|
|
|
interferon gamma
vs control in Homo sapiens (endothelial cell)
|
|
|
interferon alpha
vs control in Homo sapiens (fibroblast)
|
|
|
E-GEOD-4028
Transcription profiling of rat anterior pituitary gland of the ACI treated with diethylstilbestrol (DES) from Copenhagen and Brown Norway strains.
|
|
|
diethylstilbestrol
vs control in Rattus norvegicus (ACI)
|
|
|
diethylstilbestrol
vs control in Rattus norvegicus (Brown Norway)
|
|
|
diethylstilbestrol
vs control in Rattus norvegicus (Copenhagen)
|
|
|
E-GEOD-4036
Transcription profiling of human cerebellum from schizophrenia patients and normal subjects
|
|
|
schizophrenia
vs normal in Homo sapiens
|
|
|
E-GEOD-4065
Transcription profiling of skeletal muscle in AMPK gamma3 mutant (R225Q) transgenic mice and wild type littermates
|
|
|
AMPK gamma-3 R225Q mutant
vs wild_type in Mus musculus
|
|
|
E-GEOD-411
Transcription profiling of bone marrow-derived macrophages from SOCS3+/+ and SOCS3-/- mice to study the effects of SOCS3 on the transcriptional responses of the macrophages to IL-6.
|
|
|
100 m
vs 0 in Mus musculus (SOCS3-/-)
|
|
|
400 m
vs 0 in Mus musculus (SOCS3-/-)
|
|
|
E-GEOD-4130
Transcription profiling of Rattus norvegicus hypothalamoneurohypophyseal system from euhydrated and dehydrated animals
|
|
|
dehydration
vs control in Rattus norvegicus (neurointermediate lobe)
|
|
|
dehydration
vs control in Rattus norvegicus (paraventricular nucleus)
|
|
|
dehydration
vs control in Rattus norvegicus (supraoptic nucleus)
|
|
|
E-GEOD-415
Transcription profiling of models of cardiac remodelling: myocardial infarction or transverse aortic constriction in left ventricle free wall and septum
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart intra-ventricular septum)
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart left ventricle free wall)
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart intra-ventricular septum)
|
|
|
myocardial infarction
vs sham surgery in Mus musculus (heart left ventricle free wall)
|
|
|
E-GEOD-4262
Transcription profiling of colon, ileum, jejunum and liver from wild type and hepatic cytochrome P-450 reductase null mice treated with quercetin to identify differential transcriptional responses to quercetin.
|
|
|
quercetin
vs none in Mus musculus (wild_type & colon)
|
|
|
quercetin
vs none in Mus musculus (POR null & ileum)
|
|
|
POR null
vs wild_type in Mus musculus (none & ileum)
|
|
|
quercetin
vs none in Mus musculus (POR null & colon)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & ileum)
|
|
|
quercetin
vs none in Mus musculus (wild_type & ileum)
|
|
|
quercetin
vs none in Mus musculus (POR null & jejunum)
|
|
|
POR null
vs wild_type in Mus musculus (none & colon)
|
|
|
POR null
vs wild_type in Mus musculus (none & jejunum)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & jejunum)
|
|
|
quercetin
vs none in Mus musculus (wild_type & jejunum)
|
|
|
quercetin
vs none in Mus musculus (POR null & liver)
|
|
|
POR null
vs wild_type in Mus musculus (none & liver)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & liver)
|
|
|
quercetin
vs none in Mus musculus (wild_type & liver)
|
|
|
POR null
vs wild_type in Mus musculus (quercetin & colon)
|
|
|
E-GEOD-434
Transcription profiling of mouse inner medullary collecting duct cells treated with aldosterone to characterize early aldosterone-responsive genes.
|
|
|
aldosterone
vs control in Mus musculus
|
|
|
E-GEOD-4425
Transcription profiling of human acute monocytic leukemia cell line THP-1 cells incubated at 37 or 32 degrees C for 24h reveals moderate hypothermia produces substantial changes in cellular gene expression, in categories potentially of importance to systemic function.
|
|
|
hypothermic - 32 degree_C
vs control - 37 degree_C in Homo sapiens
|
|
|
E-GEOD-444
Transcription profiling of human CaCo-2 epithelial cells treated with vitamin D vs. controls suggests induced genes could be involved in the antiproliferative effects of vitamin D
|
|
|
1,25-dihydroxyvitamin D3
vs control in Homo sapiens
|
|
|
E-GEOD-4463
Transcription profiling of mouse during myogenesis in novel cell lines from extraocular and hindlimb muscle reveals distinctive morphological and gene/protein expression signatures
|
|
|
4 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
12 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
24 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
48 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
4 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
12 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
24 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
48 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
4 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
12 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
24 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
48 h
vs 0 in Mus musculus (extraocular muscle)
|
|
|
4 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
12 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
24 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
48 h
vs 0 in Mus musculus (gastrocnemius muscle)
|
|
|
E-GEOD-4479
Transcription profiling of mouse splenic CD4+ cells after surgical induction of sepsis vs. controls reveals a distinct transcriptional response 6 hours after sepsis induction
|
|
|
septic peritonitis
vs reference in Mus musculus
|
|
|
E-GEOD-4488
Transcription profiling of blood from human pituitary adenoma predisposition (PAP) patients to characterize the genetic basis of low penetrance tumor susceptibility
|
|
|
pituitary adenoma predisposition
vs normal in Homo sapiens
|
|
|
E-GEOD-4518
Transcription profiling of mouse expressing non-cleavable transmembrane mutant form of murine TNFalpha, or treated with soluble TNFalpha (20ng/ml) for 4 hours to investigate divergent and convergent effects on gene expression and function in acute versus chronic endothelial activation
|
|
|
soluble tumor necrosis factor alpha
vs control in Mus musculus
|
|
|
transmembrane tumor necrosis factor alpha
vs control in Mus musculus
|
|
|
E-GEOD-4537
Transcription profiling of mouse primary visual cortext from animals treated with monocular deprivation (MD), dark rearing and controls reveals binding protein of Insulin-like Growth Factor 1 is highly upregulated after MD
|
|
|
dark reared
vs control in Mus musculus
|
|
|
monocular deprivation left eyelid sutured
vs control in Mus musculus
|
|
|
monocular deprivation right eyelid sutured
vs control in Mus musculus
|
|
|
dark reared
vs control in Mus musculus
|
|
|
monocular deprivation left eyelid sutured
vs control in Mus musculus
|
|
|
monocular deprivation right eyelid sutured
vs control in Mus musculus
|
|
|
dark reared
vs control in Mus musculus
|
|
|
monocular deprivation left eyelid sutured
vs control in Mus musculus
|
|
|
monocular deprivation right eyelid sutured
vs control in Mus musculus
|
|
|
E-GEOD-4567
Transcription profiling of human pulmonary artery endothelial cell culture treated with Chapel Hill Ultrafine particle
|
|
|
ultrafine particles
vs control in Homo sapiens
|
|
|
E-GEOD-4587
Transcription profiling of human normal skin, benign and atypical nevi, and early and advanced-stage melanomas to gain insights into the genetic profile of every stage of the melanoma progression pathway
|
|
|
lymph node metastasis
vs normal in Homo sapiens
|
|
|
metastatic growth phase melanoma
vs normal in Homo sapiens
|
|
|
E-GEOD-4623
Transcription profiling of mouse NFIA deficient mice brain
|
|
|
NFI-A null
vs wild_type in Mus musculus (E18)
|
|
|
NFI-A null
vs wild_type in Mus musculus (P16)
|
|
|
E-GEOD-464
Transcription profiling time course analyzing the molecular events in rat spinal cord sections following mechanical injury
|
|
|
mild spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 21 d)
|
|
|
moderate spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 21 d)
|
|
|
severe spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 21 d)
|
|
|
mild spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 2 d)
|
|
|
moderate spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 2 d)
|
|
|
severe spinal cord injury
vs normal in Rattus norvegicus (spinal cord (T10) & 2 d)
|
|
|
E-GEOD-4656
Transcription profiling of brown adipose tissue in a glycerol kinase (Gyk) knockout mouse model to define GyK's role in insulin resistance
|
|
|
Gyk knockout
vs wild_type in Mus musculus
|
|
|
E-GEOD-466
Transcription profiling of 16-week-old mdx mouse muscles to characterize transcriptional changes induced by dystrophin deficiency.
|
|
|
mdx
vs wild_type in Mus musculus
|
|
|
E-GEOD-467
Transcription profiling of rat polysomal and total RNA samples from skeletal muscle following acute exercise to investigate translationally and transcriptionally regulated genes in muscle hypertrophy
|
|
|
1 h
vs 0 h in Rattus norvegicus (no exercise & polysomal_RNA)
|
|
|
E-GEOD-4702
Transcription profiling of spontaneously hypertensive and Sprague Dawley rat lung tissue from subjects exposed to sulfur dioxide and controls
|
|
|
sulfur dioxide
vs none in Rattus norvegicus (spontaneously hypertensive)
|
|
|
sulfur dioxide
vs none in Rattus norvegicus (Sprague Dawley)
|
|
|
E-GEOD-4757
Transcription profiling of human neurons with and without neurofibriallary tangles from Alzheimer's patients
|
|
|
neurofibriallary tangle
vs normal in Homo sapiens
|
|
|
E-GEOD-4786
Transcription profiling of cochleae from young and middle aged mice subjected to calorie restriction to examine age-related changes and calorie restriction-induced changes in gene expression in the cochlea.
|
|
|
calorie-restricted diet
vs normal diet in Mus musculus (4 months)
|
|
|
E-GEOD-4816
Transcription profiling of mouse bladder in wild type and EGFP/EYFP reporter gene transgenic mice to determine if the use of markers alters gene expression in the bladder
|
|
|
EGFP transgenic
vs wild_type in Mus musculus
|
|
|
EYFP transgenic
vs wild_type in Mus musculus
|
|
|
E-GEOD-4866
Transcription profiling of mouse cochlea to investigate the role of mtDNA mutations in age-related hearing loss in mice carrying a mutator DNA polymerase gamma
|
|
|
PolgD257A/D257A
vs wild_type in Mus musculus
|
|
|
E-GEOD-5057
Transcription profiling of human airway epithelium, large airways, from phenotypically normal smokers vs non-smokers
|
|
|
smoker
vs non-smoker in Homo sapiens
|
|
|
E-GEOD-5090
Transcription profiling of human omental adipose tissue in women with polycystic ovary syndrome (PCOS)
|
|
|
polycystic ovary syndrome
vs normal in Homo sapiens
|
|
|
E-GEOD-5101
Transcription profiling time series of Rattus norvegicus skeletal muscle samples following a single acute dose of methylprednisolone
|
|
|
168 h
vs 0 in Rattus norvegicus
|
|
|
6 h
vs 0 in Rattus norvegicus
|
|
|
10 h
vs 0 in Rattus norvegicus
|
|
|
13 h
vs 0 in Rattus norvegicus
|
|
|
18 h
vs 0 in Rattus norvegicus
|
|
|
24 h
vs 0 in Rattus norvegicus
|
|
|
36 h
vs 0 in Rattus norvegicus
|
|
|
48 h
vs 0 in Rattus norvegicus
|
|
|
72 h
vs 0 in Rattus norvegicus
|
|
|
96 h
vs 0 in Rattus norvegicus
|
|
|
E-GEOD-5106
Transcription profiling of human skeletal muscle from HIV-infected men experiencing weight loss treated with testosterone
|
|
|
testosterone
vs placebo in Homo sapiens
|
|
|
E-GEOD-5140
Transcription profiling of brains from mice with or without creatine supplementation to study the molecular mechanism of creatine improving health and life span in mice.
|
|
|
creatine
vs control in Mus musculus
|
|
|
E-GEOD-5222
Transcription profiling of human retinoblastoma samples to compare the transcriptomes of retinoblastoma with LOH on 16q to tumors without alterations on 16q
|
|
|
16q LOH
vs control in Homo sapiens
|
|
|
E-GEOD-5282
Transcription profiling of Rattus norvegicus astrocytes treated with epidermal growth factor (EGF)
|
|
|
epidermal growth factor
vs none in Rattus norvegicus (4 h)
|
|
|
epidermal growth factor
vs none in Rattus norvegicus (12 h)
|
|
|
E-GEOD-5320
Transcription profiling of brains from wild type and beta4 nicotinic acetylcholine receptor (nAChR) subunit deficient mice to identify genes that might be related to beta4-containing nAChRs activity
|
|
|
beta4-/-
vs wild_type in Mus musculus
|
|
|
E-GEOD-5324
Transcription profiling of human wild-type and TTP-deficient fibroblast cell lines to identify TTP mRNA targets
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 90 m)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 120 m)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (control & 0)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 30 m)
|
|
|
tristetrapolin-deficient
vs wild_type in Mus musculus (actinomycin D & 60 m)
|
|
|
E-GEOD-5339
Transcription profiling of human lung fibroblasts exposed to vanadium pentoxide to identifiy genes associated with vanadium pentoxide-induced bronchitis
|
|
|
hydrogen peroxide
vs control in Homo sapiens (4 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (4 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (1 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (8 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (8 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (1 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (12 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (12 h)
|
|
|
hydrogen peroxide
vs control in Homo sapiens (24 h)
|
|
|
vanadium pentoxide
vs control in Homo sapiens (24 h)
|
|
|
E-GEOD-5370
Transcription profiling of human muscle biopsies from pre-treatment dermatomyostitis patients vs. normal controls to define molecular pathways in muscle of myositis patients.
|
|
|
dermatomyositis
vs normal in Homo sapiens
|
|
|
E-GEOD-5371
Transcription profiling of 2 cell mouse embryos of BRG1 mice and wild type mice to understand the effects of BRG1 on zygotic genome activation.
|
|
|
Brg1 null
vs wild_type in Mus musculus
|
|
|
E-GEOD-5388
Transcription profiling of human brain tissue from subjects with bipolar disorder and healthy controls
|
|
|
bipolar disorder
vs normal in Homo sapiens
|
|
|
E-GEOD-5389
Transcription profiling of human post-mortem brain tissue (orbitofrontal cortex) from patients with bipolar disorder and matched healthy controls
|
|
|
bipolar disorder
vs normal in Homo sapiens (female)
|
|
|
bipolar disorder
vs normal in Homo sapiens (male)
|
|
|
E-GEOD-5390
Transcription profiling of human adult postmortem brain tissue from Down syndrome and healthy control subjects
|
|
|
Down syndrome
vs normal in Homo sapiens
|
|
|
E-GEOD-5497
Transcription profiling of C2C12 myoblasts treated with and without sodium pyruvate to examine the impact of altering energy provision on mitochondrial biogenesis in muscle cells
|
|
|
sodium pyruvate
vs none in Mus musculus
|
|
|
E-GEOD-5500
Transcription profiling of hearts from mice heterozygous for Gata4 mutation (G4D) to investigate the significance of Gata4 in regulating postnatal heart function and in regulating the hypertrophic response of the heart to pathological stress.
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (Gata4+/-)
|
|
|
Gata4+/-
vs wild_type in Mus musculus (sham surgery)
|
|
|
Gata4+/-
vs wild_type in Mus musculus (transverse aortic constriction)
|
|
|
transverse aortic constriction
vs sham surgery in Mus musculus (wild_type)
|
|
|
E-GEOD-5550
Transcription profiling of human CD43+ cells from chronic-phase untreated CML patients vs controls to determine a molecular signature
|
|
|
chronic myelogenous leukemia
vs normal in Homo sapiens
|
|
|
E-GEOD-5563
Transcription profiling of human vulvar epithelial neoplasia vs normal controls
|
|
|
vulvar intraepithelial neoplasia
vs normal in Homo sapiens
|
|
|
E-GEOD-5581
Transcription profiling of retinae from wildtype and retinoschisin knockout mice (Rs1h-/Y) at postnatal day 7 to understand the effect of retinoschisin on gene expression
|
|
|
Rs1h null
vs wild_type in Mus musculus
|
|
|
E-GEOD-5583
Transcription profiling of embryonic stem cells from wild type and histone deacetylase 1 (HDAC1) knock out mice to identify putative HDAC1 target genes.
|
|
|
HDAC1-/-
vs wild_type in Mus musculus
|
|
|
E-GEOD-5654
Transcription profiling of hematopoietic stem cells in the preleukemic phase from wiltype mice and mice deficient in transcription factor PU.1 to identify transcriptional changes preceding malignant transformation
|
|
|
PU.1 deficient
vs wild_type in Mus musculus
|
|
|
E-GEOD-5666
Transcription profiling of brains from cognitively impaired and unimpaired old rats and young rats at zero or 21 days post water maze training, and untrained individuals
|
|
|
21 d
vs 0 in Rattus norvegicus (4-6 months & trained & cognitively impaired)
|
|
|
21 d
vs 0 in Rattus norvegicus (4-6 months & trained & cognitively unimpaired)
|
|
|
21 d
vs 0 in Rattus norvegicus (24-26 months & trained & cognitively unimpaired)
|
|
|
E-GEOD-5679
Transcription profiling of human freshly isolated PPARg and RARa ligand treated dendritic cells
|
|
|
AM580
vs control in Homo sapiens
|
|
|
rosiglitazone
vs control in Homo sapiens
|
|
|
E-GEOD-5786
Transcription profiling of striata from PGC-1a knockout mice and litter mate controls to understand the roles of PGC-1a.
|
|
|
PGC-1alpha null
vs wild_type in Mus musculus
|
|
|
E-GEOD-5800
Transcription profiling of skin from interferon regulatory factor 6 (Irf6) knockout mice and wild type mice to study the role for Irf6 in epidermal development.
|
|
|
Irf6 null
vs wild_type in Mus musculus
|
|
|
E-GEOD-5823
RNAi profiling of human cancer cell lines depleted for c-MYC depletion
|
|
|
c-MYC knockdown
vs control in Homo sapiens (MCF-7 & breast cancer)
|
|
|
c-MYC knockdown
vs control in Homo sapiens (HeLa & cervical cancer)
|
|
|
E-GEOD-5901
Transcription profiling of mouse prostate after castration and hormone replacement
|
|
|
testosterone
vs none in Mus musculus (castration & 3 d)
|
|
|
E-GEOD-6085
Transcription profiling of mouse cytotoxic T lymphocyte cell line CTLL-2 treated with interleukin-2
|
|
|
12 h
vs 0 in Mus musculus (control)
|
|
|
24 h
vs 0 in Mus musculus (control)
|
|
|
interleukin-2
vs control in Mus musculus (12 h)
|
|
|
interleukin-2
vs control in Mus musculus (24 h)
|
|
|
E-GEOD-6119
Transcription profiling of rat chondrocytes treated with glucosamine exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta
|
|
|
glucosamine
vs control in Rattus norvegicus
|
|
|
interleukin 1 beta
vs control in Rattus norvegicus
|
|
|
interleukin 1 beta and glucosamine
vs control in Rattus norvegicus
|
|
|
E-GEOD-614
Transcription profiling of mouse embryonic stem (ES) cells to study the effect of Abca1 +/- mutations in ES cells.
|
|
|
Abca1 +/-
vs wild_type in Mus musculus
|
|
|
Cdk4 +/-
vs wild_type in Mus musculus
|
|
|
E-GEOD-620
Transcription profiling of human IB3-1 bronchial epithelial cell line treated with 4-phenylbutyrate treatment demonstrates a major influence on heat-shock proteins sampled at various time points
|
|
|
12 h
vs 0 in Homo sapiens
|
|
|
24 h
vs 0 in Homo sapiens
|
|
|
12 h
vs 0 in Homo sapiens
|
|
|
24 h
vs 0 in Homo sapiens
|
|
|
E-GEOD-6210
Transcription profiling of mouse PGC1beta E3,4-/E3,4- mutants reveals hypomorphic mutation in PGC1beta causes mitochondrial dysfunction and liver insulin resistance
|
|
|
PGC-1beta mutant
vs wild_type in Mus musculus (liver)
|
|
|
PGC-1beta mutant
vs wild_type in Mus musculus (quadriceps muscle)
|
|
|
E-GEOD-6297
Transcription profiling of mouse livers from animals fed four different diets
|
|
|
chimpanzee diet
vs control diet in Mus musculus
|
|
|
human cafe diet
vs control diet in Mus musculus
|
|
|
human fast food diet
vs control diet in Mus musculus
|
|
|
E-GEOD-6323
Transcription profiling of skeletal muscles from young, old, and old calorie restricted C57BL/6NHsd mice to investigate age-related changes in the transcriptional profile.
|
|
|
calorie-restricted diet
vs normal diet in Mus musculus (5 months)
|
|
|
E-GEOD-6364
Transcription profiling of human endometrium from patients with a history of endometriosis vs. normal controls sampled at a range of menstrual cycle timepoints reveals progesterone resistance and candidate susceptibility genes in women with endometriosis
|
|
|
endometriosis
vs normal in Homo sapiens (early secretory phase)
|
|
|
endometriosis
vs normal in Homo sapiens (mid secretory phase)
|
|
|
endometriosis
vs normal in Homo sapiens (proliferative phase)
|
|
|
E-GEOD-6443
Transcription profiling of jejunums from wild type and Klf9-/- mice to investigate the involvement of Klf9 in small intestine crypt-villus cell renewal and lineage determination.
|
|
|
Klf9 null
vs wild_type in Mus musculus
|
|
|
E-GEOD-6461
Transcription profiling of tumors excised from SYT-SSX synovial sarcoma mouse model to obtain insights into differential expression in synovial sarcoma.
|
|
|
synovial sarcoma
vs normal in Mus musculus
|
|
|
E-GEOD-6467
Transcription profiling of mouse brain after twelve week treatment with the antipsychotics Clozapine and Haloperidol
|
|
|
clozapine
vs none in Mus musculus
|
|
|
haloperidol
vs none in Mus musculus
|
|
|
E-GEOD-6511
Transcription profiling of mouse brain from animals treated for 4 weeks with the antipsychotics Clozapine and Haloperidol
|
|
|
clozapine
vs control in Mus musculus
|
|
|
haloperidol
vs control in Mus musculus
|
|
|
E-GEOD-6527
Transcription profiling of mouse Earlybird mutants and knockout of Rab3a on gene expression in the cerebral cortex and hippocampus
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & cerebral cortex)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & cerebral cortex)
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & hippocampus)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & hippocampus)
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & cerebral cortex)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & cerebral cortex)
|
|
|
rab3a D77G mutant
vs wild_type in Mus musculus (litter 1 & hippocampus)
|
|
|
rab3a knockout
vs wild_type in Mus musculus (litter 2 & hippocampus)
|
|
|
E-GEOD-6613
Transcription profiling of human patients with Parkinson's disease (50), 33 patients with neurodegenerative diseases other than PD, and 23 healthy controls
|
|
|
Alzheimer's disease
vs normal in Homo sapiens
|
|
|
Parkinson's disease
vs normal in Homo sapiens
|
|
|
progressive supranuclear palsy
vs normal in Homo sapiens
|
|
|
E-GEOD-6614
Transcription profiling of mouse brains following nicotine-induced seizures
|
|
|
Alpha7 L250T heterozygous
vs wild_type in Mus musculus (nicotine)
|
|
|
Alpha7 nAChR subunit L250T heterozygous
vs wild_type in Mus musculus (none)
|
|
|
nicotine
vs none in Mus musculus (Beta4 nAChR subunit null)
|
|
|
Beta4 nAChR subunit null
vs wild_type in Mus musculus (nicotine)
|
|
|
Beta4 nAChR subunit null
vs wild_type in Mus musculus (none)
|
|
|
nicotine
vs none in Mus musculus (wild_type)
|
|
|
E-GEOD-6623
Transcription profiling of bone marrow hematopoietic stem cells and myeloid progenitors from FoxO deficient mice to investigate the role of FoxO transcription factors as mediators of hematopoietic stem cell resistance to oxidative stress.
|
|
|
FoxO deficient
vs wild_type in Mus musculus (hematopoietic stem cell)
|
|
|
FoxO deficient
vs wild_type in Mus musculus (myeloid progenitor cell)
|
|
|
E-GEOD-6662
Transcripition profiling of mouse heart from cardiac-specific conditional knockout deletion of menage-a-trois-1 (MAT1)
|
|
|
MAT1 ablation
vs control in Mus musculus (2 weeks)
|
|
|
MAT1 ablation
vs control in Mus musculus (4 weeks)
|
|
|
E-GEOD-6688
Transcription profiling of lungs from wild type and MyD88 knockout mice infected with Chlamydia pneumoniae to explore the influence of MyD88 on induction of immune responses.
|
|
|
MyD88 null
vs wild_type in Mus musculus (Chlamydia pneumoniae)
|
|
|
Chlamydia pneumoniae
vs mock infected in Mus musculus (MyD88 null)
|
|
|
Chlamydia pneumoniae
vs mock infected in Mus musculus (wild_type)
|
|
|
MyD88 null
vs wild_type in Mus musculus (mock infected)
|
|
|
E-GEOD-6691
Transcription profiling of human blood and bone marrow samples from patients with Waldenstron's macroglobulinemia, chronic lymphocytic leukemia (CLL), multiple myeloma and normal individuals to indentify genes with functions in B-cell differentiation and oncogenesis
|
|
|
chronic lymphocytic leukemia
vs normal in Homo sapiens (B lymphocyte)
|
|
|
multiple myeloma
vs normal in Homo sapiens (plasma cell)
|
|
|
Waldenstrom's macroglobulinemia
vs normal in Homo sapiens (B lymphocyte)
|
|
|
Waldenstrom's macroglobulinemia
vs normal in Homo sapiens (plasma cell)
|
|
|
E-GEOD-6731
Transcription profiling of human colon biopsies obtained from patietnst with ulcerative colitis, Chrohns disease vs. normal to identify pathogenic processes underlying these disease subtypes
|
|
|
Crohn's disease
vs normal in Homo sapiens
|
|
|
ulcerative colitis
vs normal in Homo sapiens
|
|
|
E-GEOD-6740
Transcription profiling of human CD4+/CD8+ T cells obtained from HIV patients at various stages of disease vs. uninfected individuals reveals HIV infection induces a persistent T cell transcriptional profile
|
|
|
early HIV infection
vs uninfected in Homo sapiens (CD4+ T cell)
|
|
|
early HIV infection
vs uninfected in Homo sapiens (CD8+ T cell)
|
|
|
non-progressive HIV infection
vs uninfected in Homo sapiens (CD4+ T cell)
|
|
|
non-progressive HIV infection
vs uninfected in Homo sapiens (CD8+ T cell)
|
|
|
chronic HIV infection
vs uninfected in Homo sapiens (CD4+ T cell)
|
|
|
chronic HIV infection
vs uninfected in Homo sapiens (CD8+ T cell)
|
|
|
E-GEOD-6766
Transcription profiling of mouse C2C12 myotubes treated overnight with 500 uM palmitate or 1% BSA to identify mediators of obesity-linked reductions in PGC-1.
|
|
|
palmitate
vs control - BSA in Mus musculus
|
|
|
E-GEOD-6802
Transcription profiling of human bronchial airway epithelial cells infected with P. aeruginosa, S.aureus or respiratory syncytial virus vs uninfected controls to investigate the role of epithelial cells upon infection of airway pathogens
|
|
|
Pseudomonas aeruginosa
vs uninfected in Homo sapiens
|
|
|
respiratory syncytial virus
vs uninfected in Homo sapiens
|
|
|
E-GEOD-685
Transcription profiling timecourse of induced DACH1 expression in a human breast cancer cell line
|
|
|
18 h
vs 0 in Homo sapiens
|
|
|
36 h
vs 0 in Homo sapiens
|
|
|
E-GEOD-6858
Transcription profiling of whole mouse lungs of wild-type and recombinase activating gene (RAG) deficient animals sensitized and then challenged with the allergen ovalbumin
|
|
|
ovalbumin
vs control in Mus musculus (wild_type & BALB/c)
|
|
|
ovalbumin
vs control in Mus musculus (RAG null mutant & BALB-RAG)
|
|
|
E-GEOD-6879
Transcription profiling of Rattus norvegicus mammary gland tissue from animals fed on a soy protein isolate, genistein or control casein diet
|
|
|
genistein diet
vs control diet in Rattus norvegicus
|
|
|
soy protein isolate diet
vs control diet in Rattus norvegicus
|
|
|
E-GEOD-6883
Transcription profiling of human normal, non-tumorigenic breast cancer cells and CD44+CD24-/low tumorigenic breast cancer cells to generate a invasiveness gene signature
|
|
|
non-tumorigenic cancer cell
vs normal in Homo sapiens
|
|
|
non-tumorigenic cancer cell
vs normal in Homo sapiens
|
|
|
E-GEOD-691
Transcription profiling of the effect of successive steps of laser capture microdissection using Rattus norvegicus liver samples treated with clofibrate
|
|
|
stained
vs untreated in Rattus norvegicus (none & )
|
|
|
stained
vs untreated in Rattus norvegicus (clofibric acid & 0.29 %)
|
|
|
stained
vs untreated in Rattus norvegicus (clofibric acid & 0.54 %)
|
|
|
E-GEOD-6955
Transcription profiling of human super frontal gyrus (post mortem brain) from Rett syndrome patients and age sex matched controls reveals FXYD1, an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice
|
|
|
Rett syndrome
vs normal in Homo sapiens
|
|
|
E-GEOD-697
Transcription profiling of human coxsackievirus B3 (CVB3) infected HeLa cells (multiple time points and triplicate sample per time point)
|
|
|
U0126
vs none in Homo sapiens (coxsackievirus B3 & 9 h)
|
|
|
coxsackievirus B3
vs uninfected in Homo sapiens (none & 9 h)
|
|
|
coxsackievirus B3
vs uninfected in Homo sapiens (none & 0 h)
|
|
|
3 h
vs 0 h in Homo sapiens (none & coxsackievirus B3)
|
|
|
9 h
vs 0 h in Homo sapiens (none & coxsackievirus B3)
|
|
|
0.5 h
vs 0 h in Homo sapiens (none & uninfected)
|
|
|
3 h
vs 0 h in Homo sapiens (none & uninfected)
|
|
|
9 h
vs 0 h in Homo sapiens (none & uninfected)
|
|
|
coxsackievirus B3
vs uninfected in Homo sapiens (none & 3 h)
|
|
|
E-GEOD-7002
Transcription profiling time course of the response of Rattus norvegicus nasal epithelial cells to clinical_treatment with various doses of formaldehyde
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 5 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 6 h)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 6 h)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 5 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 8 d)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 8 d)
|
|
|
2 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 19 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 19 d)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 19 d)
|
|
|
6 ppm
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 24 h)
|
|
|
400 mM
vs 0 mM in Rattus norvegicus (inhalation & formaldehyde & 24 h)
|
|
|
E-GEOD-7020
Transcription profiling of mouse spleens of wild type mice and mutants lacking Nix, a proapoptotic BH3-only factor that is transcriptionally induced during erythropoiesis
|
|
|
Nix null mutant
vs wild_type in Mus musculus
|
|
|
E-GEOD-703
Transcription profiling of human peripheral blood mononuclear (PBMC) cells in pulmonary arterial hypertension
|
|
|
pulmonary arterial hypertension
vs normal in Homo sapiens
|
|
|
E-GEOD-7041
Transcription profiling of Rattus norvegicus mechanically ventilated lungs from strains resistant or susceptible to ventilation-associated lung injury (VALI)
|
|
|
high tidal volume ventilation
vs control in Rattus norvegicus (ventilation-associated lung injury (VALI) sensitive & Brown Norway)
|
|
|
high tidal volume ventilation
vs control in Rattus norvegicus (ventilation-associated lung injury (VALI) resistant & Dahl salt-sensitive)
|
|
|
E-GEOD-7137
Transcription profiling of mouse livers and quadriceps muscles of Kruppel-like factor 15 (KLF15) null mutants after an overnight fast to provide insight into the role of KLF15 in gluconeogenesis
|
|
|
KLF15 null
vs wild_type in Mus musculus (liver)
|
|
|
KLF15 null
vs wild_type in Mus musculus (quadriceps skeletal muscle)
|
|
|
E-GEOD-7146
Transcription profiling of human skeletal muscle to assess the effect of insulin infusion
|
|
|
insulin
vs none in Homo sapiens
|
|
|
insulin
vs none in Homo sapiens
|
|
|
E-GEOD-7216
Transcription profiling of human epidermal keratinocytes (NHEK) from neonatal foreskin treated with IL20 subfamily cytokines vs. controls suggests potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis
|
|
|
IL-26
vs control - untreated in Homo sapiens
|
|
|
IL-24
vs control - untreated in Homo sapiens
|
|
|
IL-22
vs control - untreated in Homo sapiens
|
|
|
IL-20
vs control - untreated in Homo sapiens
|
|
|
IL-19
vs control - untreated in Homo sapiens
|
|
|
E-GEOD-7257
Transcription profiling of mouse wild type and Lim1-null renal vesicles microdissected from embryonic day 12.5 kidneys
|
|
|
Lim1 mutant
vs wild_type in Mus musculus
|
|
|
E-GEOD-7377
Transcription profiling of human pre-malignant breast cancer samples
|
|
|
benign hyperplastic enlarged lobular unit
vs normal terminal duct lobular unit in Homo sapiens
|
|
|
E-GEOD-758
Transcription profiling of human optic nerve head (ONH) astrocyte exposed to either 60 mm Hg hydrostatic pressure (HP) or control ambient pressure (CP) to identify HP-responsive genes
|
|
|
6 h
vs 0 in Homo sapiens (ambient pressure)
|
|
|
24 h
vs 0 in Homo sapiens (ambient pressure)
|
|
|
48 h
vs 0 in Homo sapiens (ambient pressure)
|
|
|
E-GEOD-7621
Transcription profiling of human substantia nigra from postmortem brain of Parkinsons disease patients (PD)
|
|
|
Parkinson's disease
vs normal in Homo sapiens (female)
|
|
|
Parkinson's disease
vs normal in Homo sapiens (male)
|
|
|
E-GEOD-7664
Transcription profiling of human PBMC response to benzene metabolites
|
|
|
1,2,4-benzenetriol
vs control in Homo sapiens
|
|
|
E-GEOD-7669
Transcription profiling of human synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients
|
|
|
non steroidal anti-inflammatory drugs
vs none in Homo sapiens (osteoarthritis)
|
|
|
E-GEOD-7694
Transcription profiling of mouse Cannabinoid receptor double knockouts (Cnr1 -/- /Cnr2 -/-) in CHS model to investigate cutaneous contact hypersensitivity
|
|
|
dinitrofluorobenzene
vs control in Mus musculus (Cnr1 -/- /Cnr2 -/-)
|
|
|
Cnr1 -/- /Cnr2 -/-
vs wild_type in Mus musculus (control)
|
|
|
Cnr1 -/- /Cnr2 -/-
vs wild_type in Mus musculus (dinitrofluorobenzene)
|
|
|
dinitrofluorobenzene
vs control in Mus musculus (wild_type)
|
|
|
E-GEOD-7699
Transcription profiling of mouse livers from animals fed a ketogenic diet (KD), a diet high in fat and low in carbohydrates
|
|
|
ketogenic diet
vs control diet in Mus musculus
|
|
|
E-GEOD-7708
Transcription profiling of human LNCaP cells to investigate androgen receptor mediated gene expression by a sequence-specific DNA binding polyamide
|
|
|
bicalutamide and dihydrotestoterone
vs control polyamide and dihydrotestoterone in Homo sapiens
|
|
|
dihydrotestoterone
vs control polyamide and dihydrotestoterone in Homo sapiens
|
|
|
WGWWCW polyamide and dihydrotestoterone
vs control polyamide and dihydrotestoterone in Homo sapiens
|
|
|
E-GEOD-8000
Transcription profiling of mouse heart samples from individuals with homozygous or heterozygous mutant alleles of Lamin A (LMNA)
|
|
|
LmnaH222P/H222P
vs wild_type in Mus musculus
|
|
|
LmnaH222P/+
vs wild_type in Mus musculus
|
|
|
E-GEOD-8077
Transcription profiling of rat experimental model of knee osteoarthritis
|
|
|
osteoarthritic ipsilateral cartilage
vs normal contralateral cartilage in Rattus norvegicus
|
|
|
osteoarthritic ipsilateral cartilage
vs sham surgery cartilage in Rattus norvegicus
|
|
|
E-GEOD-8150
Transcription profiling of mouse brain to identify age-related transcriptional changes and the effect of dietary supplementation of vitamin E
|
|
|
alpha-tocopherol
vs none in Mus musculus (5 months)
|
|
|
alpha-tocopherol + gamma-tocopherol
vs none in Mus musculus (5 months)
|
|
|
E-GEOD-833
Transcription profiling of human post mortem spinal cord grey matter from sporadic and familial ALS patients vs controls to identify amyotrophic lateral sclerosis (ALS) associated genes
|
|
|
sporadic amyotrophic lateral sclerosis
vs reference in Homo sapiens
|
|
|
E-GEOD-85
Transcription profiling of wild type and aire -/- murine meduallary thymic epithelial cells to study the immunological roles of aire protein in thymus.
|
|
|
aire -/-
vs wild_type in Mus musculus
|
|
|
E-GEOD-8514
Transcription profiling of human normal adrenal gland and aldosterone-producing adenoma
|
|
|
aldosterone-producing adenoma
vs reference in Homo sapiens
|
|
|
E-GEOD-8700
Transcription profiling of rat fat tissues from diet-induced obesity model
|
|
|
diet-induced obesity
vs reference in Rattus norvegicus
|
|
|
E-GEOD-8972
Transcription profiling of mouse developing and mature Nrl -/- retina (Yoshida et al. 2004, HMG)
|
|
|
Nrl null
vs wild_type in Mus musculus (2 days)
|
|
|
Nrl null
vs wild_type in Mus musculus (10 days)
|
|
|
Nrl null
vs wild_type in Mus musculus (60 days)
|
|
|
E-GEOD-9723
Transcription profiling of human gingival epithelial cells responses to pathogenic oral microbial species.
|
|
|
Aggregatibacter actinomycetemcomitans
vs uninfected in Homo sapiens
|
|
|
Porphyromonas gingivalis
vs uninfected in Homo sapiens
|
|
|
E-GEOD-977
Transcription profiling of olfactory bulbs from GFAP transgenic mice and wild type mice.
|
|
|
GFAP+/+
vs wild_type in Mus musculus (23 d)
|
|
|
GFAP+/+
vs wild_type in Mus musculus (120 d)
|
|
|
E-GEOD-9914
Transcription profiling of mouse knock in mutant model for spinocerebellar ataxia type 1 and type 7 - symptomatic Sca1154Q/2Q and Sca7266Q/5Q cerebellum
|
|
|
SCA1 knock-in
vs SCA1 wild_type in Mus musculus (5 weeks)
|
|
|
SCA7 knock-in
vs SCA7 wild_type in Mus musculus (9 weeks)
|
|
|
E-MEXP-1005
Transcription profiling of scrapie ME7-infected and mock-infected mouse brains at two important preclinical time points and at terminal stages
|
|
|
scrapie ME7
vs mock infected in Mus musculus (90 days)
|
|
|
scrapie ME7
vs mock infected in Mus musculus (120 days)
|
|
|
scrapie ME7
vs mock infected in Mus musculus (150 days)
|
|
|
E-MEXP-101
RNAi on human RKO colon carcinoma cells treated with 100 nM of either SIM2s control or antisense oligos timecourse
|
|
|
SIM2s
vs control in Homo sapiens (18 h)
|
|
|
SIM2s
vs control in Homo sapiens (24 h)
|
|
|
SIM2s
vs control in Homo sapiens (10 h)
|
|
|
SIM2s
vs control in Homo sapiens (14 h)
|
|
|
E-MEXP-1025
Transcription profiling of rat spinal cord with experimental autoimmune encephalomyelitis at 3 disease points, acute, relapsing and recovering vs. controls
|
|
|
experimental autoimmune encephalomyelitis (acute)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (recovery)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (relapsing)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (acute)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (recovery)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (relapsing)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (acute)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (recovery)
vs normal in Rattus norvegicus
|
|
|
experimental autoimmune encephalomyelitis (relapsing)
vs normal in Rattus norvegicus
|
|
|
E-MEXP-1040
Transcription profiling of testis from Foxa3 knock-out mice
|
|
|
Foxa3 knockout
vs wild_type in Mus musculus
|
|
|
E-MEXP-1050
Transcription profiling of decidua basalis from women with normal pregnancies or preeclampsia and/or fetal growth restriction
|
|
|
fetal growth restriction
vs normal in Homo sapiens
|
|
|
preeclampsia
vs normal in Homo sapiens
|
|
|
E-MEXP-1077
Transcription profiling of liver from rats treated with triiodothyronine at 0.1ug or 5ug after 1 or 3 hours
|
|
|
5 ug
vs 0 ug in Rattus norvegicus (triiodothyronine & 1 h)
|
|
|
E-MEXP-1121
Transcription profiling of microdissected human pancreatic tissues and pancreas cell lines (data in addition to E-MEXP-950)
|
|
|
pancreatic ductal adenocarcinoma
vs normal in Homo sapiens ( & epithelial cell)
|
|
|
E-MEXP-1159
Transcription profiling of mouse SAP102 and PSD-95 knockouts compared to their wild-type littermates
|
|
|
PSD95/dlgh4 -/-
vs wild_type in Mus musculus
|
|
|
SAP102/dlgh3 -/Y
vs wild_type in Mus musculus
|
|
|
E-MEXP-1171
Transcription profiling of human colorectal carcinoma cell line HCT116 treated with SN38 (7-ethyl-10-hydroxy-20(S)-camptothecin)and sampled at 3 timepoints
|
|
|
6 h
vs 0 h in Homo sapiens (SN38 sensitive)
|
|
|
12 h
vs 0 h in Homo sapiens (SN38 sensitive)
|
|
|
24 h
vs 0 h in Homo sapiens (SN38 sensitive)
|
|
|
E-MEXP-1184
Transcription profiling of mouse hippocampal slices after NMDA or forskolin-rolipram-0 Mg2+ or bicuculline treatment
|
|
|
bicuculline
vs none in Mus musculus
|
|
|
forskolin + rolipram in Mg2+-free ACSF
vs none in Mus musculus
|
|
|
N-methyl-D-aspartic acid
vs none in Mus musculus
|
|
|
E-MEXP-1194
Transcription profiling of human colorectal cancer epithelial (HCT116) p53 null cells treated with SN38 for 6, 12 and 24h
|
|
|
6 h
vs 0 h in Homo sapiens
|
|
|
12 h
vs 0 h in Homo sapiens
|
|
|
24 h
vs 0 h in Homo sapiens
|
|
|
E-MEXP-1195
Transcription profiling of rat to investigate effects of hyperglycaemi and genetic background on gene expression
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (Wistar Kyoto)
|
|
|
E-MEXP-1235
Transcription profiling of human HepG2 cells expressing gain-of-function mutant D374Y-PCSK9
|
|
|
D374Y-PCSK9
vs wild_type in Homo sapiens
|
|
|
E-MEXP-1240
Transcription profiling of Cited2 knockout mouse E14.5 fetal liver samples
|
|
|
Cited2 -/-
vs wild_type in Mus musculus
|
|
|
E-MEXP-1254
Transcription profiling of mouse macrophages infected with Leishmania major or Leishmania donovani
|
|
|
Leishmania donovani
vs uninfected in Mus musculus (Mus musculus)
|
|
|
Leishmania major
vs uninfected in Mus musculus (Mus musculus)
|
|
|
phagocytosis of latex beads
vs uninfected in Mus musculus (Mus musculus)
|
|
|
E-MEXP-1275
Transcription profiling of CD14+ monocytes in biopolar disorder patients and controls
|
|
|
bipolar disorder
vs normal in Homo sapiens
|
|
|
E-MEXP-1278
Transcription profiling of rat carotid artery following arteriotomy
|
|
|
arteriotomy
vs control in Rattus norvegicus (4 h)
|
|
|
arteriotomy
vs control in Rattus norvegicus (7 d)
|
|
|
arteriotomy
vs control in Rattus norvegicus (48 h)
|
|
|
E-MEXP-1328
Transcription profiling of human intestinal mucosa after exposure to Lactobacillus plantarum WCFS1
|
|
|
Lactobacillus plantarum WCFS1
vs mock infected in Homo sapiens
|
|
|
E-MEXP-1331
Transcription profiling of normal, tumor and pure stromal tissue samples from patients with prostate adenocarcinoma, together with 4 cell lines
|
|
|
adenocarcinoma
vs normal in Homo sapiens ( & & prostate)
|
|
|
E-MEXP-1371
Transcription profiling of mouse T-cell thymocytes and bone marrow-derived macrophages dervied from Upf2fl/fl;LysMCre and Upf2fl/fl;LckCre mice to test the importance of nonsense-mediated mRNA decay on global transcription
|
|
|
Upf2fl/fl;LckCre
vs wild_type in Mus musculus (thymocyte)
|
|
|
Upf2fl/fl;LysMCre
vs wild_type in Mus musculus (macrophage)
|
|
|
E-MEXP-1372
Transcription profiling of human colon Caco-2 cells treated with extracts from broccoli that had been cooked for different lengths of time
|
|
|
1 m
vs 0 m in Homo sapiens (cooked broccoli)
|
|
|
E-MEXP-1413
Transcription profiling of liver from mouse EF2 mutants vs wild type to investigate the role of E2F2 in liver regeneration
|
|
|
E2F2-/-
vs wild_type in Mus musculus (0 h)
|
|
|
48 h
vs 0 h in Mus musculus (E2F2-/-)
|
|
|
48 h
vs 0 h in Mus musculus (wild_type)
|
|
|
E2F2-/-
vs wild_type in Mus musculus (48 h)
|
|
|
E-MEXP-1431
Transcription profiling of intestine from wild type and Mdm2 knock-out mice
|
|
|
mdm2 knock-out
vs wild_type in Mus musculus
|
|
|
E-MEXP-1444
Transcription profiling of Mac-1+, c-Kit+ myeloid progenitor cells from mice homozygous for the p42-specific knock-out Cebpa mutation and independently transplanted with leukemic bone marrow, and from control mice heterozygous for Cebpa mutation
|
|
|
acute myeloid leukemia
vs normal in Mus musculus
|
|
|
E-MEXP-1503
Transcription profiling of liver from wild type or Ercc1 mutant mice
|
|
|
Ercc1
vs wild_type in Mus musculus
|
|
|
E-MEXP-438
Transcription profiling of liver-specific transcription in Mtf1 conditional knockout mice and control littermates to identify MTF-1 target genes and cadmium-inducible genes in the adult liver
|
|
|
20 umol/kg
vs 0 umol/kg in Mus musculus (cadmium & & Mtf1-loxP)
|
|
|
20 umol/kg
vs 0 umol/kg in Mus musculus (cadmium & gene_knock_out & Mtf1-Mx-cre)
|
|
|
E-MEXP-456
RNAi knock down of human miR-30a-3p HepG2 cells using siRNA duplex against the miRNA precursor, and vs control cells on GeneChip to identify the target transcripts against miR-30a-3p in vivo
|
|
|
miR-30a-3p siRNA duplex
vs none in Homo sapiens
|
|
|
E-MEXP-459
Transcription profiling of mouse primary microglial cultures with and without neurovirulent (FrCasE) and non-neurovirulent (Fr57E) virus infection
|
|
|
Fr57E
vs mock infected in Mus musculus
|
|
|
FrCasE
vs mock infected in Mus musculus
|
|
|
E-MEXP-476
Transcription profiling of CD146 immunomagnetically enriched circulating endothelial cells (CECs) from healthy donors and patients with metastatic breast, colorectal, prostate, lung and renal cancer
|
|
|
breast cancer
vs normal in Homo sapiens
|
|
|
E-MEXP-490
Transcription profiling of the effect of metformin (50 mg/kg, 400 mg/kg) on gene expression in livers of db/db mice
|
|
|
50 mg/kg
vs 0 mg/kg in Mus musculus (metformin)
|
|
|
400 mg/kg
vs 0 mg/kg in Mus musculus (metformin)
|
|
|
E-MEXP-515
Transcription profiling of diabetic neuropathy in dorsal root ganglia from streptozotocin-diabetic male wistar rats over the first 8 weeks of diabetes
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (4 weeks)
|
|
|
diabetes mellitus
vs normal in Rattus norvegicus (8 weeks)
|
|
|
E-MEXP-532
Transcription profiling of mesenchymal stem cells exposed to CM from tumor cells or bone marrow
|
|
|
C85 tumor cell conditioned media
vs normal growth media (C85) in Rattus norvegicus (single exposure)
|
|
|
E-MEXP-548
siRNA knock-down of human RNA Binding IMP Proteins vs mock treated cells
|
|
|
IMP(1,3)A
vs mock in Homo sapiens
|
|
|
IMP(1,3)B
vs mock in Homo sapiens
|
|
|
E-MEXP-549
Transcription profiling time course of gene expression following irradiation to identify P53 activity
|
|
|
2 h
vs 0 in Homo sapiens
|
|
|
4 h
vs 0 in Homo sapiens
|
|
|
6 h
vs 0 in Homo sapiens
|
|
|
8 h
vs 0 in Homo sapiens
|
|
|
10 h
vs 0 in Homo sapiens
|
|
|
12 h
vs 0 in Homo sapiens
|
|
|
E-MEXP-558
Transcription profiling of mouse with ablation of connexin 30 in the stria vascularis
|
|
|
Connexin 30-/-
vs wild_type in Mus musculus
|
|
|
E-MEXP-561
Transcription profiling of human lymphatic endothelial cells response to Kaposi-sarcoma herpesvirus
|
|
|
Kaposi's sarcoma
vs normal in Homo sapiens ( & )
|
|
|
Kaposi's sarcoma-associated herpesvirus
vs uninfected in Homo sapiens (lymphatic endothelial cell & normal)
|
|
|
E-MEXP-563
Transcription profiling of human mesenchymal stem cells transformed with lentiviral vectors of TERT, E6, SV40 and RAS
|
|
|
hTERT/HPVE6/HPVE7 transfection
vs none in Homo sapiens
|
|
|
hTERT/HPVE6 transfection
vs none in Homo sapiens
|
|
|
hTERT transfection
vs none in Homo sapiens
|
|
|
hTERT/HPVE6/HPVE7/SV40t/hRas transfection
vs none in Homo sapiens
|
|
|
hTERT/HPVE6/HPVE7/SV40t transfection
vs none in Homo sapiens
|
|
|
E-MEXP-567
Transcription profiling of human grade II astrocytic tumor (astrocytomas) vs grade IV tumors (glioblastoma)
|
|
|
astrocytic tumor
vs normal in Homo sapiens
|
|
|
glioblastoma
vs normal in Homo sapiens
|
|
|
E-MEXP-634
Transcription profiling of Gata3 conditional knock out mice to investigate epidermis and hair follicle differentiation
|
|
|
Gata3 knockout
vs wild_type in Mus musculus
|
|
|
E-MEXP-66
Transcription profiling of Kaposi's sarcoma, normal skin and primary cells
|
|
|
AIDS-KS, HIV+, nodular (late) stage
vs normal in Homo sapiens ( & skin & )
|
|
|
E-MEXP-701
Transcription profiling of mouse primary dermal fibroblasts treated with DNA demethylating agent 5-aza-2-deoxycytidine
|
|
|
5 uM
vs 0 uM in Mus musculus (5-aza-2'-deoxycytidine)
|
|
|
E-MEXP-731
Transcription profiling of hippocampus from wild type and CIC-6 knock-out mice
|
|
|
ClC-6 -/- knockout
vs wild_type in Mus musculus
|
|
|
E-MEXP-755
Transcription profiling of thymotyctes from parp-2 -/- mice to determine whether dis-regulation of a genetic pathway could explain the increased apoptosis of these cells
|
|
|
parp-2 deficient
vs wild_type in Mus musculus
|
|
|
E-MEXP-858
Transcription profiling time series of human mesenchymal stem cells after induction of differentiation
|
|
|
1 h
vs 0 h in Homo sapiens
|
|
|
3 h
vs 0 h in Homo sapiens
|
|
|
7 d
vs 0 h in Homo sapiens
|
|
|
9 h
vs 0 h in Homo sapiens
|
|
|
E-MEXP-882
Transcription profiling of normal and cancerous human breast cell lines and tissues to explore HOXA gene expression in context of other homological genes and in context of physical location in genome
|
|
|
breast cancer
vs normal in Homo sapiens
|
|
|
infiltrating ductal carcinoma
vs normal in Homo sapiens
|
|
|
infiltrating lobular carcinoma
vs normal in Homo sapiens
|
|
|
E-MEXP-886
Transcription profiling of ataxin-null (Atxn-null) vs. wild type mice to investigate spinocerebellar ataxia type 1 (SCA1)
|
|
|
ataxin 1 -/-
vs wild_type in Mus musculus
|
|
|
E-MEXP-891
Transcription profiling of mammary glands from wild type and Akt1 knock out lactating mice at day 9 after parturition
|
|
|
Akt1 -/-
vs wild_type in Mus musculus
|
|
|
E-MEXP-893
Transcription profiling of hepatocytes from mice that are hyperglycaemic, obese and insulin resistant as a result of being fed a high fat diet
|
|
|
hyperglycaemic, obese and insulin resistant
vs normal in Mus musculus
|
|
|
hyperglycaemic, obese and insulin resistant
vs normal in Mus musculus
|
|
|
E-MEXP-923
Transcription profiling of mice with transgenic expression of the transcription factor Klf5 in esophageal epithelia compared to littermate controls
|
|
|
ED-L2/Klf5 transgenic
vs wild_type in Mus musculus
|
|
|
E-MEXP-939
Transcription profiling of mouse skeletal muscle samples from PGC-1 beta transgenic vs. wild type to investigate the role of transcriptional coactivator PGC-1 alpha in the formation of type I and IIa muscle fibers.
|
|
|
PGC-1 beta transgenic
vs wild_type in Mus musculus
|
|
|
E-MEXP-950
Transcription profiling of human microdissected pancreas ductal adenocarcinoma vs. microdissected normal duct cells
|
|
|
pancreatic cancer
vs normal in Homo sapiens
|
|
|
E-MEXP-976
Transcription profiling of dorsal root ganglia from rats treated with SNT to find genes responsible for mechanical hypersensitivity
|
|
|
spinal nerve transection
vs sham surgery in Rattus norvegicus
|
|
|
E-MEXP-999
Transcription profiling of rat uterus after exposure to 17 alpha-ethynyl estradiol for different lengths of time
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 2 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 1 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 8 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 24 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 48 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 72 h)
|
|
|
10 ug_per_kg
vs 0 ug_per_kg in Rattus norvegicus (17a-ethynylestradiol & 96 h)
|
|
|
E-TABM-102
Transcription profiling of wild type and ATF3 -/- mouse bone marrow macrophages stimulated with lipopolysaccharide for 1, 2, 4, 8 and 24 hours
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (lipopolysaccharide & 10 ng_per_mL & 4 h)
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (lipopolysaccharide & 10 ng_per_mL & 8 h)
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (none & & )
|
|
|
ATF3 -/-
vs wild_type in Mus musculus (lipopolysaccharide & 10 ng_per_mL & 1 h)
|
|
|
E-TABM-12
Transcription profiling of rat testis by transplacental exposure to estrogen receptor (ER) agonists - high and low doses of 17a-Ethynyl estradiol, genistein or bisphenol A
|
|
|
0.02 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
0.5 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
1 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
10 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
50 mg_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (genestein)
|
|
|
0.001 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
0.01 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
0.1 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
1 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
10 ug_per_kg_per_day
vs 0 mg_per_kg_per_day in Rattus norvegicus (17a-ethynylestradiol)
|
|
|
E-TABM-232
Transcription profiling of wild type and bic-deficient mouse T cells
|
|
|
bic-deficient
vs wild_type in Mus musculus (Th1)
|
|
|
bic-deficient
vs wild_type in Mus musculus (Th2)
|
|
|
E-TABM-304
Transcription profiling of pancreata from wild type, KrasG12D, Ela-Tgfa and KrasG12D; Ela-Tgfa mice
|
|
|
Ela-Tgfa
vs wild_type in Mus musculus
|
|
|
p48-Cre;KrasG12D
vs wild_type in Mus musculus
|
|
|
p48-Cre;KrasG12D;Ela-Tgfa
vs wild_type in Mus musculus
|
|
|
E-TABM-310
Transcription profiling of wild type, Atf3(-/-), Ticam1(-/-), MyD88(-/-) and CREM(-/-) murine bone marrow-derived macrophages stimulated with purified Toll-like receptor agonists after 0-48 hours
|
|
|
CREM(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 1080 m)
|
|
|
CREM(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 40 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (none & 0 m)
|
|
|
CREM(-/-)
vs wild_type in Mus musculus (none & 0 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 40 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 120 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 720 m)
|
|
|
ATF3(-/-)
vs wild_type in Mus musculus (lipopolysaccharide & 1080 m)
|
|
|
E-TABM-367
Transcription profiling of limb buds from E12.5 wild type and POR conditional knock out mice
|
|
|
Prx1Cre/+;PORlox/lox
vs wild_type in Mus musculus
|
|
|
E-TABM-411
Transcription profiling of mouse wild type and pkd1-/- kidney epithelial cells with and without fluid flow
|
|
|
pkd1 -/-
vs wild_type in Mus musculus (flow)
|
|
|
pkd1 -/-
vs wild_type in Mus musculus (no flow)
|
|
|
E-TABM-90
Transcription profiling of irradiated human lymphyocytes from prostate carcinoma patients following curative radiotherapy to study late radiation toxicity
|
|
|
2 Gy
vs 0 Gy in Homo sapiens (non responder)
|
|
|
2 Gy
vs 0 Gy in Homo sapiens (over responder)
|
|
PROSTAGLANDIN SYNTHESIS REGULATION
|
|
|
CELL CYCLE KEGG
|
|
|
HSA04610 COMPLEMENT AND COAGULATION CASCADES
|
|
|
LAIRPATHWAY
|
|
|
EICOSANOID SYNTHESIS
|
|
|
HSA04110 CELL CYCLE
|
|
|
DNA REPLICATION REACTOME
|
|
|
HSA01430 CELL COMMUNICATION
|
|
|
SMALL LIGAND GPCRS
|
|
|
G1 TO S CELL CYCLE REACTOME
|
|
|
GPCRDB CLASS B SECRETIN LIKE
|
|
|
INFLAMPATHWAY
|
|
|
HSA04614 RENIN ANGIOTENSIN SYSTEM
|
|
|
BREAST CANCER ESTROGEN SIGNALING
|
|
|
PYRIMIDINE METABOLISM
|
|
|
HSA04115 P53 SIGNALING PATHWAY
|
|
|
STATIN PATHWAY PHARMGKB
|
|
|
MRNA PROCESSING REACTOME
|
|
|
HSA04640 HEMATOPOIETIC CELL LINEAGE
|
|
|
GAMMA HEXACHLOROCYCLOHEXANE DEGRADATION
|
|
|
HSA00240 PYRIMIDINE METABOLISM
|
|
|
ATRBRCAPATHWAY
|
|
|
TOLLPATHWAY
|
|
|
IL3PATHWAY
|
|
|
HSA00071 FATTY ACID METABOLISM
|
|
|
GLUTAMATE METABOLISM
|
|
|
HSA00251 GLUTAMATE METABOLISM
|
|
|
G2PATHWAY
|
|
|
HSA04512 ECM RECEPTOR INTERACTION
|
|
|
TRYPTOPHAN METABOLISM
|
|
|
DCPATHWAY
|
|
|
G1PATHWAY
|
|
|
GPCRDB CLASS A RHODOPSIN LIKE
|
|
|
NFKBPATHWAY
|
|
|
UREA CYCLE AND METABOLISM OF AMINO GROUPS
|
|
|
HISTIDINE METABOLISM
|
|
|
HSA04670 LEUKOCYTE TRANSENDOTHELIAL MIGRATION
|
|
|
HSA03030 DNA POLYMERASE
|
|
|
NTHIPATHWAY
|
|
|
HSA04060 CYTOKINE CYTOKINE RECEPTOR INTERACTION
|
|
|
CCR5PATHWAY
|
|
|
HSA00960 ALKALOID BIOSYNTHESIS II
|
|
|
HSA03320 PPAR SIGNALING PATHWAY
|
|
|
TNFR2PATHWAY
|
|
|
HSA03050 PROTEASOME
|
|
|
TYROSINE METABOLISM
|
|
|
MPRPATHWAY
|
|
|
NDKDYNAMINPATHWAY
|
|
|
TRANSLATION FACTORS
|
|
|
ST G ALPHA I PATHWAY
|
|
|
HSA04650 NATURAL KILLER CELL MEDIATED CYTOTOXICITY
|
|
|
HSA01032 GLYCAN STRUCTURES DEGRADATION
|
|
|
HSA01510 NEURODEGENERATIVE DISEASES
|
|
|
HSA00330 ARGININE AND PROLINE METABOLISM
|
|
|
RELAPATHWAY
|
|
|
HYPERTROPHY MODEL
|
|
|
STRIATED MUSCLE CONTRACTION
|
|
|
HSA00531 GLYCOSAMINOGLYCAN DEGRADATION
|
|
|
PROSTAGLANDIN AND LEUKOTRIENE METABOLISM
|
|
|
HSA04120 UBIQUITIN MEDIATED PROTEOLYSIS
|
|
|
HSA00380 TRYPTOPHAN METABOLISM
|
|
|
CELLCYCLEPATHWAY
|
|
|
ARFPATHWAY
|
|
|
SIG PIP3 SIGNALING IN CARDIAC MYOCTES
|
|
|
HSA00340 HISTIDINE METABOLISM
|
|
|
INTEGRINPATHWAY
|
|
|
RASPATHWAY
|
|
|
SIG BCR SIGNALING PATHWAY
|
|
|
HSA05030 AMYOTROPHIC LATERAL SCLEROSIS
|
|
|
BLOOD CLOTTING CASCADE
|
|
|
HSA05110 CHOLERA INFECTION
|
|
|
UCALPAINPATHWAY
|
|
|
ST B CELL ANTIGEN RECEPTOR
|
|
|
GCRPATHWAY
|
|
|
HSA05223 NON SMALL CELL LUNG CANCER
|
|
|
FMLPPATHWAY
|
|
|
HSA04360 AXON GUIDANCE
|
|
|
PTDINSPATHWAY
|
|
|
HSA05220 CHRONIC MYELOID LEUKEMIA
|
|
|
KREBS TCA CYCLE
|
|
|
GLYCEROLIPID METABOLISM
|
|
|
EGFPATHWAY
|
|
|
HSA04350 TGF BETA SIGNALING PATHWAY
|
|
|
ANDROGEN AND ESTROGEN METABOLISM
|
|
|
HSA00480 GLUTATHIONE METABOLISM
|
|
|
TCRPATHWAY
|
|
|
ST P38 MAPK PATHWAY
|
|
|
SIG PIP3 SIGNALING IN B LYMPHOCYTES
|
|
|
ST INTEGRIN SIGNALING PATHWAY
|
|
|
INTEGRIN MEDIATED CELL ADHESION KEGG
|
|
|
ST JNK MAPK PATHWAY
|
|
|
CASPASEPATHWAY
|
|
|
ST GRANULE CELL SURVIVAL PATHWAY
|
|
|
BETA ALANINE METABOLISM
|
|
|
GLUTATHIONE METABOLISM
|
|
|
HSA05214 GLIOMA
|
|
|
ST WNT BETA CATENIN PATHWAY
|
|
|
HSA04660 T CELL RECEPTOR SIGNALING PATHWAY
|
|
|
RACCYCDPATHWAY
|
|
|
GLYCOLYSIS AND GLUCONEOGENESIS
|
|
|
PDGFPATHWAY
|
|
|
GHPATHWAY
|
|
|
IGF1PATHWAY
|
|
|
NKCELLSPATHWAY
|
|
|
NGFPATHWAY
|
|
|
CXCR4PATHWAY
|
|
|
HSA00620 PYRUVATE METABOLISM
|
|
|
SA B CELL RECEPTOR COMPLEXES
|
|
|
HSA04340 HEDGEHOG SIGNALING PATHWAY
|
|
|
HSA00260 GLYCINE SERINE AND THREONINE METABOLISM
|
|
|
HSA05217 BASAL CELL CARCINOMA
|
|
|
INTRINSICPATHWAY
|
|
|
ST MYOCYTE AD PATHWAY
|
|
|
GATA3PATHWAY
|
|
|
RAC1PATHWAY
|
|
|
HSA04810 REGULATION OF ACTIN CYTOSKELETON
|
|
|
GLYCINE SERINE AND THREONINE METABOLISM
|
|
|
NUCLEAR RECEPTORS
|
|
|
HSA04662 B CELL RECEPTOR SIGNALING PATHWAY
|
|
|
GPCRPATHWAY
|
|
|
GSK3PATHWAY
|
|
|
ST INTERLEUKIN 4 PATHWAY
|
|
|
HSA04664 FC EPSILON RI SIGNALING PATHWAY
|
|
|
OVARIAN INFERTILITY GENES
|
|
|
WNT SIGNALING
|
|
|
CARDIACEGFPATHWAY
|
|
|
HSA04012 ERBB SIGNALING PATHWAY
|
|
|
CALCINEURINPATHWAY
|
|
|
HCMVPATHWAY
|
|
|
AMIPATHWAY
|
|
|
CSKPATHWAY
|
|
|
CALCIUM REGULATION IN CARDIAC CELLS
|
|
|
HSA04370 VEGF SIGNALING PATHWAY
|
|
|
HSA04630 JAK STAT SIGNALING PATHWAY
|
|
|
ST T CELL SIGNAL TRANSDUCTION
|
|
|
HSA04510 FOCAL ADHESION
|
|
|
HSA04010 MAPK SIGNALING PATHWAY
|
|
|
HSA04930 TYPE II DIABETES MELLITUS
|
|
|
EDG1PATHWAY
|
|
|
HSA05216 THYROID CANCER
|
|
|
MONOAMINE GPCRS
|
|
|
HSA04912 GNRH SIGNALING PATHWAY
|
|
|
GPCRDB OTHER
|
|
|
HSA03022 BASAL TRANSCRIPTION FACTORS
|
|
|
HSA05222 SMALL CELL LUNG CANCER
|
|
|
UBIQUITIN MEDIATED PROTEOLYSIS
|
|
|
PHOTOSYNTHESIS
|
|
|
HSA00626 NAPHTHALENE AND ANTHRACENE DEGRADATION
|
|
|
HSA00450 SELENOAMINO ACID METABOLISM
|
|
|
HSA05212 PANCREATIC CANCER
|
|
|
ATP SYNTHESIS
|
|
|
FLAGELLAR ASSEMBLY
|
|
|
TYPE III SECRETION SYSTEM
|
|
|
HSA05120 EPITHELIAL CELL SIGNALING IN HELICOBACTER PYLORI INFECTION
|
|
|
HSA04620 TOLL LIKE RECEPTOR SIGNALING PATHWAY
|
|
|
NITROGEN METABOLISM
|
|
|
PEPTIDE GPCRS
|
|
|
RNA TRANSCRIPTION REACTOME
|
|
|
FRUCTOSE AND MANNOSE METABOLISM
|
|
|
SA CASPASE CASCADE
|
|
|
HSA04210 APOPTOSIS
|
|
|
PORPHYRIN AND CHLOROPHYLL METABOLISM
|
|
|
APOPTOSIS KEGG
|
|
|
HSA04140 REGULATION OF AUTOPHAGY
|
|
|
HSA03010 RIBOSOME
|
|
|
ST ADRENERGIC
|
|
|
HSA04740 OLFACTORY TRANSDUCTION
|
|
|
CHREBPPATHWAY
|
|
|
HSA00980 METABOLISM OF XENOBIOTICS BY CYTOCHROME P450
|
|
|
HSA00910 NITROGEN METABOLISM
|
|
|
IL2RBPATHWAY
|
|
|
STRESSPATHWAY
|
|
|
APOPTOSIS GENMAPP
|
|
|
HDACPATHWAY
|
|
|
HIVNEFPATHWAY
|
|
|
HSA00530 AMINOSUGARS METABOLISM
|
|
|
HSA00600 SPHINGOLIPID METABOLISM
|
|
|
HSA00010 GLYCOLYSIS AND GLUCONEOGENESIS
|
|
|
PHENYLALANINE METABOLISM
|
|
|
HSA00710 CARBON FIXATION
|
|
|
GLUCONEOGENESIS
|
|
|
GLYCOLYSIS
|
|
|
HSA00860 PORPHYRIN AND CHLOROPHYLL METABOLISM
|
|
|
AMINOACYL TRNA BIOSYNTHESIS
|
|
|
HSA00970 AMINOACYL TRNA BIOSYNTHESIS
|
|
|
CARBON FIXATION
|
|
|
HSA00563 GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS
|
|
|
HSA00650 BUTANOATE METABOLISM
|
|
|
HSA00051 FRUCTOSE AND MANNOSE METABOLISM
|
|
|
HSA00790 FOLATE BIOSYNTHESIS
|
|
|
HSA00252 ALANINE AND ASPARTATE METABOLISM
|
|
|
ATMPATHWAY
|
|
|
HSA01031 GLYCAN STRUCTURES BIOSYNTHESIS 2
|
|
|
HSA00500 STARCH AND SUCROSE METABOLISM
|
|
|
HSA05010 ALZHEIMERS DISEASE
|
|
|
HSA00360 PHENYLALANINE METABOLISM
|
|
|
HSA00632 BENZOATE DEGRADATION VIA COA LIGATION
|
|
|
P53PATHWAY
|
|
|
HSA00030 PENTOSE PHOSPHATE PATHWAY
|
|
|
GALACTOSE METABOLISM
|
|
|
LYSINE DEGRADATION
|
|
|
HSA00230 PURINE METABOLISM
|
|
|
PENTOSE PHOSPHATE PATHWAY
|
|
|
ALANINE AND ASPARTATE METABOLISM
|
|
|
STARCH AND SUCROSE METABOLISM
|
|
|
PURINE METABOLISM
|
|
|
CTLA4PATHWAY
|
|
|
PROPANOATE METABOLISM
|
|
|
ARGININE AND PROLINE METABOLISM
|
|
|
TOB1PATHWAY
|
|
|
HSA00640 PROPANOATE METABOLISM
|
|
|
HSA04940 TYPE I DIABETES MELLITUS
|
|
|
HSA00280 VALINE LEUCINE AND ISOLEUCINE DEGRADATION
|
|
|
VALINE LEUCINE AND ISOLEUCINE DEGRADATION
|
|
|
IL7PATHWAY
|
|
|
NKTPATHWAY
|
|
|
BUTANOATE METABOLISM
|
|
|
HSA05050 DENTATORUBROPALLIDOLUYSIAN ATROPHY
|
|
|
PYRUVATE METABOLISM
|
|
|
ST WNT CA2 CYCLIC GMP PATHWAY
|
|
|
SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTES
|
|
|
ST PHOSPHOINOSITIDE 3 KINASE PATHWAY
|
|
|
BIOPEPTIDESPATHWAY
|
|
|
IGF1MTORPATHWAY
|
|
|
CCR3PATHWAY
|
|
|
CREBPATHWAY
|
|
|
PGC1APATHWAY
|
|
|
ERKPATHWAY
|
|
|
BILE ACID BIOSYNTHESIS
|
|
|
DEATHPATHWAY
|
|
|
INOSITOL PHOSPHATE METABOLISM
|
|
|
MITOCHONDRIAPATHWAY
|
|
|
SPRYPATHWAY
|
|
|
BADPATHWAY
|
|
|
HSA00562 INOSITOL PHOSPHATE METABOLISM
|
|
|
TNFR1PATHWAY
|
|
|
HSA00220 UREA CYCLE AND METABOLISM OF AMINO GROUPS
|
|
|
APOPTOSIS
|
|
|
HSA04070 PHOSPHATIDYLINOSITOL SIGNALING SYSTEM
|
|
|
HSA04742 TASTE TRANSDUCTION
|
|
|
MTORPATHWAY
|
|
|
EPOPATHWAY
|
|
|
SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASES
|
|
|
CERAMIDEPATHWAY
|
|
|
HSA00361 GAMMA HEXACHLOROCYCLOHEXANE DEGRADATION
|
|
|
PHOSPHATIDYLINOSITOL SIGNALING SYSTEM
|
|
|
PAR1PATHWAY
|
|
|
HSA00120 BILE ACID BIOSYNTHESIS
|
|
|
CYTOKINEPATHWAY
|
|
|
G PROTEIN SIGNALING
|
|
|
CHOLESTEROL BIOSYNTHESIS
|
|
|
P53HYPOXIAPATHWAY
|
|
|
ST GAQ PATHWAY
|
|
|
HSA05040 HUNTINGTONS DISEASE
|
|
|
CIRCADIAN EXERCISE
|
|
|
ST TUMOR NECROSIS FACTOR PATHWAY
|
|
|
OXIDATIVE PHOSPHORYLATION
|
|
|
HSA00190 OXIDATIVE PHOSPHORYLATION
|
|
|
HSA03020 RNA POLYMERASE
|
|
|
PROTEASOMEPATHWAY
|
|
|
HSA00100 BIOSYNTHESIS OF STEROIDS
|
|
|
HSA05221 ACUTE MYELOID LEUKEMIA
|
|
|
VEGFPATHWAY
|
|
|
CITRATE CYCLE TCA CYCLE
|
|
|
HSA04150 MTOR SIGNALING PATHWAY
|
|
|
ST GA13 PATHWAY
|
|
|
HSA00512 O GLYCAN BIOSYNTHESIS
|
|
|
ALKPATHWAY
|
|
|
HSA01030 GLYCAN STRUCTURES BIOSYNTHESIS 1
|
|
|
HSA04910 INSULIN SIGNALING PATHWAY
|
|
|
BCRPATHWAY
|
|
|
HSA05215 PROSTATE CANCER
|
|
|
HSA04520 ADHERENS JUNCTION
|
|
|
HSA04530 TIGHT JUNCTION
|
|
|
SIG CD40PATHWAYMAP
|
|
|
HSA05130 PATHOGENIC ESCHERICHIA COLI INFECTION EHEC
|
|
|
IL1RPATHWAY
|
|
|
TIDPATHWAY
|
|
|
HSA00310 LYSINE DEGRADATION
|
|
|
PPARAPATHWAY
|
|
|
HSA00052 GALACTOSE METABOLISM
|
|
|
VIPPATHWAY
|
|
|
41BBPATHWAY
|
|
|
ETSPATHWAY
|
|
|
SMOOTH MUSCLE CONTRACTION
|
|
|
SPPAPATHWAY
|
|
|
AT1RPATHWAY
|
|
|
IL12PATHWAY
|
|
|
ACTINYPATHWAY
|
|
|
HSA00020 CITRATE CYCLE
|
|
|
ST DICTYOSTELIUM DISCOIDEUM CAMP CHEMOTAXIS PATHWAY
|
|
|
SIG CHEMOTAXIS
|
|
|
HSA05218 MELANOMA
|
|
|
HSA00410 BETA ALANINE METABOLISM
|
|
|
IL6PATHWAY
|
|
|
EIF4PATHWAY
|
|
|
MEF2DPATHWAY
|
|
|
HSA00150 ANDROGEN AND ESTROGEN METABOLISM
|
|
|
IL2PATHWAY
|
|
|
HSA04920 ADIPOCYTOKINE SIGNALING PATHWAY
|
|
|
HSA04950 MATURITY ONSET DIABETES OF THE YOUNG
|
|
|
HSA00602 GLYCOSPHINGOLIPID BIOSYNTHESIS NEO LACTOSERIES
|
|
|
GLYCOSPHINGOLIPID METABOLISM
|
|
|
HSA00590 ARACHIDONIC ACID METABOLISM
|
|
|
NOS1PATHWAY
|
|
|
HSA04080 NEUROACTIVE LIGAND RECEPTOR INTERACTION
|
|
|
HSA00565 ETHER LIPID METABOLISM
|
|
|
RHOPATHWAY
|
|
|
GLYCEROPHOSPHOLIPID METABOLISM
|
|
|
KERATINOCYTEPATHWAY
|
|
|
HSA00903 LIMONENE AND PINENE DEGRADATION
|
|
|
ST GA12 PATHWAY
|
|
|
ST DIFFERENTIATION PATHWAY IN PC12 CELLS
|
|
|
FCER1PATHWAY
|
|
|
ST ERK1 ERK2 MAPK PATHWAY
|
|
|
PYK2PATHWAY
|
|
|
GLEEVECPATHWAY
|
|
|
HSA05211 RENAL CELL CARCINOMA
|
|
|
TPOPATHWAY
|
|
|
ST FAS SIGNALING PATHWAY
|
|
|
HSA04320 DORSO VENTRAL AXIS FORMATION
|
|
|
HSA04020 CALCIUM SIGNALING PATHWAY
|
|
|
ECMPATHWAY
|
|
|
HSA02010 ABC TRANSPORTERS GENERAL
|
|
|
HSA00760 NICOTINATE AND NICOTINAMIDE METABOLISM
|
|
|
CARM ERPATHWAY
|
|
|
HSA00564 GLYCEROPHOSPHOLIPID METABOLISM
|
|
|
HSA00510 N GLYCAN BIOSYNTHESIS
|
|
|
N GLYCAN BIOSYNTHESIS
|
|
|
HSA00561 GLYCEROLIPID METABOLISM
|
|
|
HSA00350 TYROSINE METABOLISM
|
|
|
HSA04310 WNT SIGNALING PATHWAY
|
|
|
CALCINEURIN NF AT SIGNALING
|
|
|
NO1PATHWAY
|
|
|
HSA04612 ANTIGEN PROCESSING AND PRESENTATION
|
|
|
HSA05131 PATHOGENIC ESCHERICHIA COLI INFECTION EPEC
|
|
|
HSA00534 HEPARAN SULFATE BIOSYNTHESIS
|
|
|
HSA04130 SNARE INTERACTIONS IN VESICULAR TRANSPORT
|
|
|
INSULINPATHWAY
|
|
|
SIG IL4RECEPTOR IN B LYPHOCYTES
|
|
|
HSA04330 NOTCH SIGNALING PATHWAY
|
|
|
HSA04514 CELL ADHESION MOLECULES
|
|
|
HSA00591 LINOLEIC ACID METABOLISM
|
|
|
STEMPATHWAY
|
|
|
CHEMICALPATHWAY
|
|
|
CK1PATHWAY
|
|
|
NFATPATHWAY
|
|
|
ERK5PATHWAY
|
|
|
HSA04540 GAP JUNCTION
|
|
|
HSA04720 LONG TERM POTENTIATION
|
|
|
WNTPATHWAY
|
|
|
FASPATHWAY
|
|
|
P38MAPKPATHWAY
|
|
|
RIBOSOMAL PROTEINS
|
|
|
MAPKPATHWAY
|
|
|
HSA04916 MELANOGENESIS
|
|
|
HSA05219 BLADDER CANCER
|
|
|
HSA05213 ENDOMETRIAL CANCER
|
|
|
HSA00670 ONE CARBON POOL BY FOLATE
|
|
|
MCALPAINPATHWAY
|
|
|
HSA00271 METHIONINE METABOLISM
|
|
|
HSA00624 1 AND 2 METHYLNAPHTHALENE DEGRADATION
|
|
|
HSA00272 CYSTEINE METABOLISM
|
|
|
METPATHWAY
|
|
|
HSA00770 PANTOTHENATE AND COA BIOSYNTHESIS
|
|
|
HSA00532 CHONDROITIN SULFATE BIOSYNTHESIS
|
|
|
HSA00740 RIBOFLAVIN METABOLISM
|
|
|
HSA00440 AMINOPHOSPHONATE METABOLISM
|
|
|
HSA05210 COLORECTAL CANCER
|
|
|
HSA04730 LONG TERM DEPRESSION
|
|
|
HSA00604 GLYCOSPHINGOLIPID BIOSYNTHESIS GANGLIOSERIES
|
|
|
HSA05020 PARKINSONS DISEASE
|
|
|
CDMACPATHWAY
|
|
|
TH1TH2PATHWAY
|
|
|
SA TRKA RECEPTOR
|
|
|
SA MMP CYTOKINE CONNECTION
|
|
|
TELPATHWAY
|
|
|
PTENPATHWAY
|
|
|
SA PTEN PATHWAY
|
|
|
HSA00592 ALPHA LINOLENIC ACID METABOLISM
|
|
|
NO2IL12PATHWAY
|